

【業績集】 2016-2025 年

【2025 年】

■原著

1. Imaizumi T, Hasegawa T, Kosugi T, Nishiwaki H, Abe M, Hanafusa N, Honda H, Tsuruya K, Ito Y, Kuragano T. Renal anemia and hyporesponsiveness to ESA for preservation of residual kidney function in patients undergoing peritoneal dialysis. *Sci Rep.* 2025 Jan 21;15(1):2689.
2. Kato T, Nakatsuka R, Zhang R, Uemura Y, Yamashita H, Matsuoka Y, Shirouzu Y, Fujioka T, Hattori F, Ogata H, Sakashita A, Honda H, Hitomi H. The role of glial cells missing 2 in induced pluripotent stem cell parathyroid differentiation. *Tissue Cell.* 2025 Feb;92:102634.
3. Kosugi T, Hasegawa T, Imaizumi T, Nishiwaki H, Honda H, Ito Y, Tsuruya K, Abe M, Hanafusa N, Kuragano T. Association between hemoglobin level and mortality in patients undergoing maintenance hemodialysis: a nationwide dialysis registry in Japan. *Clin Exp Nephrol.* 2025 Jun;29(6):831-842.
4. Imaizumi T, Hasegawa T, Kosugi T, Nishiwaki H, Honda H, Tsuruya K, Ito Y, Kuragano T. Management of anaemia and prognosis of patients undergoing maintenance peritoneal dialysis: A nationwide cohort study. *Perit Dial Int.* 2025 Jul;45(4):214-223.
5. Aoki S, Saito T, Yoshida S, Shibagaki K, Hirao K, Yuza T, Honda H. Associations of roxadustat with copper elevation and hypothyroidism in patients on hemodialysis. *Int Urol Nephrol.* 2026 Feb;58(2):681-690.
6. Nishiwaki H, Imaizumi T, Hasegawa T, Kosugi T, Maruyama Y, Tsuruya K, Ito Y, Honda H, Abe M, Hanafusa N, Kuragano T. Association between Serum Iron Store Biomarkers and All-Cause Mortality in Japanese Patients Undergoing Hemodialysis: A Nationwide Cohort Study. *Am J Nephrol.* 2025;56(3):318-328.
7. Kosugi T, Hasegawa T, Imaizumi T, Nishiwaki H, Honda H, Ito Y, Tsuruya K, Abe M, Hanafusa N, Kuragano T. Nutritional Status Modifies the Association Between Hemoglobin Level and Mortality in Older Patients Undergoing Hemodialysis: A Nationwide Dialysis Registry in Japan. *J Ren Nutr.* 2025 May;35(3):443-453.
8. Suzuki T, Nishiwaki H, Abe Y, Watanabe Y, Yoshida S, Kanazawa N, Noma H, Ota E, Honda H, Hasegawa T. Discontinuation of Renin-Angiotensin System Inhibitors and Clinical Outcomes: A Systematic Review and Meta-Analysis of Randomized Controlled Trial. *Am J Nephrol.* 2025 Nov 28:1-12.

9. Yoshida K, Saito T, Kato T, Takezaki T, Kato N, Mizobuchi M, Ogata H, Koiwa F, Honda H. Phosphate binder pill burden and cardiovascular events in patients undergoing hemodialysis. *Ther Apher Dial.* 2025 Jun;29(3):333-344.
10. Saito T, Mizobuchi M, Yamakawa A, Kagimura T, Ogata H, Fukagawa M, Hirakata H, Akizawa T, Honda H. Association of serum phosphate levels and statin use with cardiovascular events in Japanese patients on chronic haemodialysis: a post-hoc analysis of the LANDMARK trial. *Clin Kidney J.* 2025 May 19;18(6):sfaf151.
11. Kato T, Yoshida K, Abe M, Yamashita M, Kobayashi K, Saito T, Takezaki T, Kato N, Mizobuchi M, Koiwa F, Ogata H, Honda H. PTH variability is associated with increased risk of mortality in Japanese hemodialysis patients. *Clin Exp Nephrol.* 2026 Jan;30(1):135-144.
12. Akizawa T, Urano N, Ikejiri K, Nakanishi K, Fukagawa M. Tenapanor: A novel therapeutic agent for dialysis patients with hyperphosphatemia. *Ther Apher Dial.* 2025 Apr;29(2):157-169.
13. Hamano T, Koiwa F, Isaka Y, Yokoyama K, Fukagawa M, Inagaki Y, Watanabe YS, Honda D, Akizawa T. Long-Term Efficacy and Safety of Upacicalcet in Japanese Hemodialysis Patients with Secondary Hyperparathyroidism: Open-Label 52-Week Study. *Am J Nephrol.* 2025;56(1):70-84.
14. McCullough KP, Morgenstern H, Rayner HC, Port FK, Jadoul MY, Akizawa T, Pisoni RL, Herman WH, Robinson BM; DOPPS 7 (2018-2021) Country Investigators. Explaining International Trends in Mortality on Hemodialysis Through Changes in Hemodialysis Practices in the Dialysis Outcomes and Practice Patterns Study (DOPPS). *Am J Kidney Dis.* 2025 Jan;85(1):25-35.e1.

■ 書籍・総説

1. 本田 浩一. 【腎疾患治療薬 フロントライン】(第2章)慢性腎臓病・透析合併症 腎性貧血治療薬 HIF-PH 阻害薬 ダプロデュスタット. 腎と透析 (0385-2156)99 巻増刊 Page256-261 (2025. 11)
2. 齋藤 友広, 青木 崇吾, 河守 咲季, 本田 浩一. 【腎性貧血の最新動向-2025 年版 CKD 患者における腎性貧血治療ガイドラインの要点と実践】HIF-PH 阻害薬と血清銅, セルロプラスミン. 腎と透析 (0385-2156)99 巻 3 号 Page423-427 (2025. 09)
3. 本田 浩一, 阿部 一輝, 河守 咲季. 【腎性貧血の最新動向-2025 年版 CKD 患者における腎性貧血治療ガイドラインの要点と実践】2025 年版日本透析医学会「慢性腎臓病患者における腎性貧血治療のガイドライン」の要点と適切な活用に向けて 鉄関連因子の評価. 腎と透析 (0385-2156)99 巻 3 号 Page392-396 (2025. 09)

4. 齋藤 友広, 下村 知輝, 河守 紗季, 本田 浩一. 【CKD-MBD -進歩と革新】 MBD とアウトカム 血清リン(生命予後, 心血管病と目標値). 腎と透析 (0385-2156)98 巻 5 号 Page622-626 (2025. 05)
5. 本田 浩一. 【慢性腎臓病(CKD)「CKD 診療ガイドライン 2023」および「CKD 診療ガイド 2024」の要点】 CKD 診療の実際 「CKD 診療ガイドライン 2023」 および「CKD 診療ガイド 2024」のエッセンス 腎代替療法に関する Shared Decision Making(SDM). Medical Practice(0910-1551)42 巻 6 号 Page895-898 (2025. 06)

【2024 年】

■原著

1. Shimokawa M, Kajio Y, Kawanishi K, Kawanishi K, Shiomi M, Morikawa T, Sasai F, Baba M, Kang D, Takaki T, Suzuki T, Koiwa F, Honda K, Honda H. Acute Tubular Injury and Fanconi Syndrome Associated With Red Yeast Rice Supplement. *Kidney Int Rep.* 2024 Dec 26;10(3):956-959.
2. Fliser D, Bhandari S, Ortiz A, Santos V, Khalife N, Jiletcovici A, Akizawa T. Roxadustat Efficacy and Safety in Patients Receiving Peritoneal Dialysis: Pooled Analysis of Four Phase 3 Studies. *J Clin Med.* 2024 Nov 8;13(22):6729.
3. Kato M, Ito H, Yamakawa A, Kagimura T, Fukagawa M, Yamamoto M, Saito Y, Akizawa T, Ogata H. Effect of aspirin on cardiovascular events in patients undergoing hemodialysis with hyperphosphatemia: A post hoc analysis of the LANDMARK trial. *Ther Apher Dial.* 2024 Aug;28(4):580-590. doi:
4. Mishina S, Ito Y, Lee T, Murofushi T, Uetake Y, Akizawa T. Physician and Patient Preferences for Treatment of Anemia Associated with Chronic Kidney Disease in Japan: A Survey Including Best-Worst Scaling. *Patient Prefer Adherence.* 2024 Jul 31;18:1563-1575.
5. Kajio Y, Suzuki T, Kobayashi K, Kanazawa N, Iyoda M, Honda H, Honda K. Activation of the inflammasome and pyroptosis cascade in podocytes of patients with minimal change disease. *Clin Kidney J.* 2024 Jul 16;17(8):sfae216.
6. Ito K, Akizawa T, Arita K, Mitobe Y, Komatsu N. Effect of ferric citrate hydrate on fibroblast growth factor 23 and platelets in non-dialysis-dependent chronic kidney disease and non-chronic kidney disease patients with iron deficiency anemia. *Clin Exp Nephrol.* 2024 Jul;28(7):636-646.
7. Saito Y, Ito H, Fukagawa M, Akizawa T, Kagimura T, Yamamoto M, Kato M, Ogata H. Effect of renin-angiotensin system inhibitors on cardiovascular events in hemodialysis patients with hyperphosphatemia: A post hoc analysis of the LANDMARK trial. *Ther Apher Dial.* 2024 Apr;28(2):192-205.

8. Hamano T, Yamaguchi Y, Goto K, Mizokawa S, Ito Y, Dellanna F, Barratt J, Akizawa T. Risk Factors for Thromboembolic Events in Patients With Dialysis-Dependent CKD: Pooled Analysis of Phase 3 Roxadustat Trials in Japan. *Adv Ther*. 2024 Apr;41(4):1526-1552. doi: 10.1007/s12325-023-02727-3.
9. Ikejiri K, Suzuki T, Muto S, Takama H, Yamawaki K, Miyazawa T, Urakawa I, Aoki Y, Otsuki A, Katsuoka F, Kinoshita K, Nangaku M, Akizawa T, Yamamoto M. Effects of NRF2 polymorphisms on safety and efficacy of bardoxolone methyl: subanalysis of TSUBAKI study. *Clin Exp Nephrol*. 2024 Mar;28(3):225-234.
10. Nakayama M, Kobayashi S, Kusakabe M, Ohara M, Nakanishi K, Akizawa T, Fukagawa M. Tenapanor for peritoneal dialysis patients with hyperphosphatemia: a phase 3 trial. *Clin Exp Nephrol*. 2024 Feb;28(2):153-164.

■書籍・総説

1. 本田 浩一. 【腎疾患の診断と治療 最前線】腎不全と腎代替療法(診断と治療)慢性腎臓病の貧血管理. 腎と透析 97 巻増刊 Page641-646(2024. 12).
2. 本田 浩一. 【腎と微量元素-鉄・銅・亜鉛を中心に】序文 腎と微量元素. 腎と透析 97 巻 5 号 Page663-666(2024. 11).
3. 梶尾 優希, 鈴木 泰平, 本田 浩一, 本田 一穂. 【感染症と腎疾患】糸球体・尿管間質疾患 IgA 優位沈着性感染関連糸球体腎炎. 腎と透析 96 巻 6 号 Page733-739(2024. 06).
4. 本田 浩一, 森川 友喜, 稲葉 大朗. 鉄と心腎連関. 医師と東京都医師会を結ぶ会報誌 77 巻 5 号 Page403-406(2024. 06)
5. 本田 浩一, 寺戸 成美. 【透析患者の腎性貧血のケアガイド 病態生理・合併症・薬物療法・食事療法まるわかり!】(1章)医師が解説!腎性貧血のあれこれ エリスロポエチン(EPO)と腎性貧血. 透析ケア 30 巻 6 号 Page518-521(2024. 06).
6. 加藤 憲, 人見 浩史, 本田 浩一. 【在宅透析】腹膜透析 腹膜中皮細胞の再生. 腎と透析 96 巻 4 号 Page455-459(2024. 04).
7. 本田 浩一, 鮫島 里沙, 美馬 友紀. 【日常診療で診る CKD-乗り遅れないための最新情報】進行した CKD と ESKD 腎性貧血. 診断と治療 112 巻 5 号 Page579-583(2024. 05).
8. 本田 浩一, 青木 崇吾. HIF-PH 阻害薬の使用症例集 使ってみて実感した HIF-PH 阻害薬の特徴(第 2 回) 腎性貧血治療薬:HIF-PH 阻害薬間の切り替えロキサデュスタットとダプロデュスタット. 臨床透析 40 巻 2 号 Page227-230(2024. 02).

【2023 年】

■原著

1. Kikuchi K, Nangaku M, Ryuzaki M, Yamakawa T, Ota Y, Hanafusa N, Sakai K, Kanno Y, Ando R, Shinoda T, Wakino S, Nakamoto H, Takemoto Y, Akizawa T; COVID-19 Task Force Committee of the Japanese Association of Dialysis Physicians, the Japanese Society for Dialysis Therapy, and the Japanese Society of Nephrology. Efficacy of molnupiravir and sotrovimab in Japanese dialysis patients with COVID-19 in clinical practice during the Omicron (BA.1 and BA.2) pandemic. *Ther Apher Dial.* 2023 Dec;27(6):1064-1069.
2. Koiwa F, Sato Y, Ohara M, Nakanishi K, Fukagawa M, Akizawa T. Long-term safety and decrease of pill burden by tenapanor therapy: a phase 3 open-label study in hemodialysis patients with hyperphosphatemia. *Sci Rep.* 2023 Nov 4;13(1):19100.
3. Fukagawa M, Urano N, Ikejiri K, Kinoshita J, Nakanishi K, Akizawa T. Tenapanor for the Treatment of Hyperphosphatemia in Japanese Hemodialysis Patients: A Randomized Phase 3 Monotherapy Study With an Up-titration Regimen. *Am J Kidney Dis.* 2023 Nov;82(5):635-637.
4. Kanazawa N, Iyoda M, Suzuki T, Tachibana S, Nagashima R, Honda H. Exploring the significance of interleukin-33/ST2 axis in minimal change disease. *Sci Rep.* 2023 Oct 31;13(1):18776.
5. Shigematsu T, Koiwa F, Isaka Y, Fukagawa M, Hagita K, Watanabe YS, Honda D, Akizawa T. Efficacy and Safety of Upacicalcet in Hemodialysis Patients with Secondary Hyperparathyroidism: A Randomized Placebo-Controlled Trial. *Clin J Am Soc Nephrol.* 2023 Oct 1;18(10):1300-1309.
6. Wada Y, Jensen C, Meyer ASP, Zonoozi AAM, Honda H. Efficacy and safety of interleukin-6 inhibition with ziltivekimab in patients at high risk of atherosclerotic events in Japan (RESCUE-2): A randomized, double-blind, placebo- controlled, phase 2 trial. *J Cardiol.* 2023 Oct;82(4):279-285.
7. Inaguma D, Koiwa F, Tokumoto M, Fukagawa M, Yoneda S, Yasuzawa H, Asano K, Hagita K, Inagaki Y, Honda D, Akizawa T. Phase 2 study of upacicalcet in Japanese haemodialysis patients with secondary hyperparathyroidism: an intraindividual dose-adjustment study. *Clin Kidney J.* 2023 Sep 4;16(12):2614-2625.
8. Iseri K, Mizobuchi M, Winzenrieth R, Humbert L, Saitou T, Kato T, Nakajima Y, Wakasa M, Shishido K, Honda H. Long-Term Effect of Denosumab on Bone Disease in Patients with CKD. *Clin J Am Soc Nephrol.* 2023 Sep 1;18(9):1195-1203.
9. Suzuki T, Iyoda M, Kanazawa N, Tachibana S, Honda H. Effect of Proprotein

Convertase Subtilisin/Kexin Type 9 Inhibition on Podocytes in Mouse Nephrotic Syndrome. *Lab Invest.* 2023 Sep;103(9):100199.

10. Maruyama S, Kurasawa S, Hayashi T, Nangaku M, Narita I, Hirakata H, Tanabe K, Morita S, Tsubakihara Y, Imai E, Akizawa T; PREDICT Investigators. Higher hemoglobin levels using darbepoetin alfa and kidney outcomes in advanced chronic kidney disease without diabetes: a prespecified secondary analysis of the PREDICT trial. *Clin Exp Nephrol.* 2023 Sep;27(9):757-766.
11. Nitta K, Itoyama S, Ikejiri K, Kinoshita J, Nakanishi K, Fukagawa M, Akizawa T. Randomized Study of Tenapanor Added to Phosphate Binders for Patients With Refractory Hyperphosphatemia. *Kidney Int Rep.* 2023 Aug 13;8(11):2243-2253.
12. Yamamoto H, Yamada T, Miyazaki K, Yamashita T, Kato T, Ohara K, Nakamura Y, Akizawa T. Treatment satisfaction with molidustat in CKD-related anemia in non-dialysis patients: a post-hoc analysis of two clinical trials. *Clin Exp Nephrol.* 2023 Aug;27(8):651-659.
13. Saito T, Mizobuchi M, Sakai M, Kawata T, Kitayama T, Kato T, Suzuki T, Ogata H, Koiwa F, Honda H. Effects of evocalcet on parathyroid calcium-sensing receptor and vitamin D receptor expression in uremic rats. *FASEB J.* 2023 Aug;37(8):e23094.
14. Iseri K, Miyakoshi C, Joki N, Onishi Y, Fukuma S, Honda H, Tsuruya K. α -Blocker Use in Hemodialysis: The Japan Dialysis Outcomes and Practice Patterns Study. *Kidney Med.* 2023 Jul 4;5(9):100698.
15. Ganz T, Locatelli F, Arici M, Akizawa T, Reusch M. Iron Parameters in Patients Treated with Roxadustat for Anemia of Chronic Kidney Disease. *J Clin Med.* 2023 Jun 22;12(13):4217. doi: 10.3390/jcm12134217.
16. Yoshida K, Mizukami T, Fukagawa M, Akizawa T, Morohoshi H, Sambe T, Takeshima A, Ito H, Ogata H, Uchida N. Effect of vitamin D receptor activators on cardiovascular events in patients on hemodialysis-A post hoc analysis of the LANDMARK study. *Ther Apher Dial.* 2023 Jun;27(3):523-529.
17. Nangaku M, Takama H, Ichikawa T, Mukai K, Kojima M, Suzuki Y, Watada H, Wada T, Ueki K, Narita I, Kashihara N, Kadowaki T, Hase H, Akizawa T. Randomized, double-blind, placebo-controlled phase 3 study of bardoxolone methyl in patients with diabetic kidney disease: design and baseline characteristics of the AYAME study. *Nephrol Dial Transplant.* 2023 May 4;38(5):1204-1216.
18. Suzuki T, Nishiwaki H, Watanabe Y, Abe Y, Noma H, Ota E, Honda H, Hasegawa T. Outcomes of discontinuing renin-angiotensin system inhibitors: a study protocol for conducting systematic review and meta-analysis. *BMJ Open.* 2023 May

- 3;13(5):e070345. doi: 10.1136/bmjopen-2022-070345.
19. Kambayashi Y, Iseri K, Morikawa T, Yao A, Yokochi A, Honda H. Risk factors for blood vessel rupture during vascular access intervention therapy for hemodialysis patients. *PLoS One*. 2023 Mar 31;18(3):e0283844.
 20. Fujii H, Hamano T, Tsuchiya K, Kuragano T, Joki N, Tsuruya K, Honda H, Uemura Y, Nitta K; PARAMOUNT Study Investigators. Not baseline but time- dependent erythropoiesis-stimulating agent responsiveness predicts cardiovascular disease in hemodialysis patients receiving epoetin beta pegol: A multicenter prospective PARAMOUNT-HD Study. *Int J Cardiol*. 2023 Mar 15;375:110-118.
 21. Yoshida S, Saito T, Shibagaki K, Hirao K, Yuza T, Tomosugi N, Honda H. Changes of biomarkers for erythropoiesis, iron metabolism, and FGF23 by supplementation with roxadustat in patients on hemodialysis. *Sci Rep*. 2023 Feb 23;13(1):3181. doi: 10.1038/s41598-023-30331-6.
 22. Yoshida K, Mizukami T, Fukagawa M, Akizawa T, Morohoshi H, Sambe T, Ito H, Ogata H, Uchida N; LANDMARK Investigators, Committees. Target phosphate and calcium levels in patients undergoing hemodialysis: a post-hoc analysis of the LANDMARK study. *Clin Exp Nephrol*. 2023 Feb;27(2):179-187.
 23. Kikuchi K, Nangaku M, Ryuzaki M, Yamakawa T, Yoshihiro O, Hanafusa N, Sakai K, Kanno Y, Ando R, Shinoda T, Wakino S, Nakamoto H, Takemoto Y, Akizawa T; COVID-19 Task Force Committee of the Japanese Association of Dialysis Physicians, the Japanese Society for Dialysis Therapy, and the Japanese Society of Nephrology. Effectiveness of SARS-CoV-2 vaccines on hemodialysis patients in Japan: A nationwide cohort study. *Ther Apher Dial*. 2023 Feb;27(1):19-23.
 24. Imasawa T, Saito C, Kai H, Iseki K, Kazama JJ, Shibagaki Y, Sugiyama H, Nagata D, Narita I, Nishino T, Hasegawa H, Honda H, Maruyama S, Miyazaki M, Mukoyama M, Yasuda H, Wada T, Ishikawa Y, Tsunoda R, Nagai K, Okubo R, Kondo M, Hoshino J, Yamagata K. Long-term effectiveness of a primary care practice facilitation program for chronic kidney disease management: an extended follow- up of a cluster-randomized FROM-J study. *Nephrol Dial Transplant*. 2023 Jan 23;38(1):158-166.
 25. Saito T, Mizobuchi M, Kato T, Suzuki T, Fujiwara Y, Kanamori N, Makuuchi M, Honda H. One-Year Romosozumab Treatment Followed by One-Year Denosumab Treatment for Osteoporosis in Patients on Hemodialysis: An Observational Study. *Calcif Tissue Int*. 2023 Jan;112(1):34-44.

1. 金澤 伸洋, 杉田 悠, 橘 翔平, 片岡 和義, 疋田 聡, 本田 浩一, 野口 智永. 透析シャント血栓性閉塞に対するマッサージおよび超音波ガイド下 PTA の経験. 腎と透析 95 巻別冊 アクセス 2023 Page148-150(2023. 10).
2. 森川 友喜, 本田 浩一. 【病因・病態生理から読み解く腎・泌尿器疾患のすべて】CKD 腎性貧血. 腎と透析 95 巻増刊 Page406-410(2023. 12).
3. 本田 浩一. 変わりゆく腎性貧血治療. 善仁会研究年報 44 号 Page1-6(2023. 03).
4. 本田 浩一. 【保存期慢性腎臓病と透析期のステージに応じた診療のポイント】 [Chapter 4] 合併症・併存疾患がある患者への対応. 内科 132 巻 1 号 Page113-116(2023. 07).
5. 鈴木 泰平, 本田 浩一. 【腎臓病外来: マネジメントとコツ】 初診 スクリーニングとコツ 尿異常へのアプローチ. 腎と透析 94 巻 4 号 Page485-491(2023. 04).

【2022 年】

■原著

1. Tokumoto M, Tokunaga S, Asada S, Endo Y, Kurita N, Fukagawa M, Akizawa T. Predictive factors requiring high-dose evocalcet in hemodialysis patients with secondary hyperparathyroidism. *PLoS One*. 2022 Dec 13;17(12):e0279078.
2. Ogata H, Fukagawa M, Hirakata H, Kagimura T, Akizawa T; LANDMARK Investigators and Committees. Effect of lanthanum carbonate and calcium carbonate on the progression of coronary artery calcification among hemodialysis patients with vascular calcification risk: a randomized controlled trial. *Clin Exp Nephrol*. 2022 Dec;26(12):1223-1232.
3. Tachibana S, Iyoda M, Suzuki T, Kanazawa N, Honda H. Serum Uromodulin Levels Reflect Severity of Clinicopathological Findings in Early Stage IgA Nephropathy. *Am J Nephrol*. 2022;53(7):575-585.
4. Suzuki T, Mizobuchi M, Yoshida S, Terado N, Aoki S, Sato N, Honda H. Romosozumab successfully regulated progressive osteoporosis in a patient with autosomal dominant polycystic kidney disease undergoing hemodialysis. *Osteoporos Int*. 2022 Dec;33(12):2649-2652.
5. Nagashima R, Ishikawa H, Kuno Y, Kohda C, Iyoda M. IL-33 attenuates renal fibrosis via group2 innate lymphoid cells. *Cytokine*. 2022 Sep;157:155963.
6. Inaba M, Une Y, Ikejiri K, Kanda H, Fukagawa M, Akizawa T. In Reply to "Letter Regarding 'Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan-A Phase 2 Randomized Trial'". *Kidney Int Rep*.

2022 Jun 1;7(7):1725-1726.

7. Akiyama M, Shimomura K, Yoshimoto H, Sako M, Kodama M, Abe K, Gunji M, Kang D, Takaki T, Wada Y, Iyoda M, Honda K. Crohn's disease may promote inflammation in IgA nephropathy: a case-control study of patients undergoing kidney biopsy. *Virchows Arch.* 2022 Oct;481(4):553-563.
8. Morohoshi A, Qureshi AR, Iseri K, Morohoshi H, Li Y, Lindholm B, Berg HE, Felländer-Tsai L. Secular trends in incidence and seasonal variation of distal radius fracture among children: A nationwide study based on the Swedish National Patient Register 2002-2016. *Bone.* 2022 Sep;162:116479.
9. Kazama JJ, Koiwa F, Yokoyama K, Fukagawa M, Asano K, Honda D, Akizawa T. First-in-Patient Phase I/II Study of Upacicalcet in Japanese Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis: Pharmacokinetic and Pharmacodynamic Properties. *Clin Pharmacokinet.* 2022 Sep;61(9):1271-1284.
10. Yoshida N, Shimozato S, Wada Y. Efficacy of monotherapy with low-density lipoprotein apheresis for severe renal disorder caused by cholesterol crystal embolization: A case report. *Ther Apher Dial.* 2022 Oct;26(5):1056-1057.
11. Koiwa F, Yazawa R, Fukagawa M, Honda D, Akizawa T. First-in-Human Phase I Study of the Novel Injectable Calcimimetic Agent Upacicalcet in Healthy Adult Japanese Participants. *Drugs R D.* 2022 Jun;22(2):131-140.
12. Nangaku M, Akizawa T, Nagakubo T, Yonekawa T, Kimura T, Endo Y, Cobitz A. Safety of daprodustat in patients with anemia of chronic kidney disease: A pooled analysis of phase 3 studies in Japan. *Ther Apher Dial.* 2022 Dec;26(6):1065-1078.
13. Koide Y, Kataoka Y, Hasegawa T, Ota E, Noma H. Effect of systemic bisphosphonate administration on patients with periodontal disease: a systematic review and meta-analysis protocol. *BMJ Open.* 2022 Mar 4;12(3):e057768.
14. Fujii N, Hamano T, Hsu JY, Imai E, Akizawa T, Nitta K, Watanabe T, Iimuro S, Ohashi Y, Matsuo S, Makino H, Hishida A, Alper AB, Horwitz EJ, Hsu CY, Porter AC, Wolf M, Yang W, Nessel L, Feldman HI. A Comparative Study of Serum Phosphate and Related Parameters in Chronic Kidney Disease between the USA and Japan. *Am J Nephrol.* 2022;53(2-3):226-239.
15. Fujikawa R, Nagao Y, Fujioka M, Akizawa T. Treatment of anemia associated with chronic kidney disease with the HIF prolyl hydroxylase inhibitor enarodustat: A review of the evidence. *Ther Apher Dial.* 2022 Aug;26(4):679-693.
16. Ikeda-Taniguchi M, Takahashi K, Shishido K, Honda H. Total iron binding capacity is a predictor for muscle loss in maintenance hemodialysis patients. *Clin Exp Nephrol.* 2022 Jun;26(6):583-592.

17. Shigematsu T, Asada S, Endo Y, Kawata T, Fukagawa M, Akizawa T. Evocalcet with vitamin D receptor activator treatment for secondary hyperparathyroidism. *PLoS One*. 2022 Feb 17;17(2):e0262829.
18. Kambayashi Y, Iseri K, Yamamoto Y, Abe M, Wada Y, Yanai R, Honda H. Bilateral renal subcapsular hematoma caused by polyarteritis nodosa: a case report. *CEN Case Rep*. 2022 Nov;11(4):399-403.
19. Inaba M, Une Y, Ikejiri K, Kanda H, Fukagawa M, Akizawa T. Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan-A Phase 2 Randomized Trial. *Kidney Int Rep*. 2021 Nov 24;7(2):177-188.
20. Kanazawa N, Iyoda M, Hayashi J, Honda K, Oda T, Honda H. A case of acute poststreptococcal glomerulonephritis complicated by interstitial nephritis related to streptococcal pyrogenic exotoxin B. *Pathol Int*. 2022 Mar;72(3):200-206.
21. Ishikawa H, Kuno Y, Kohda C, Sasaki H, Nagashima R, Iyoda M. Exopolysaccharides from *Lactobacillus delbrueckii* ssp. *bulgaricus* OLL1073R-1 prevent influenza virus infection and attenuate secondary bacterial infection risk. *Lett Appl Microbiol*. 2022 May;74(5):632-639.
22. Nakajima K, Momo K, Nimura S, Kaizaki-Mitsumoto A, Kanazawa N, Inaba T, Saito T, Wada Y, Honda H, Numazawa S, Sasaki T. Severe acyclovir-induced encephalopathy in an elderly patient with herpes zoster. *Eur J Clin Pharmacol*. 2022 Mar;78(3):527-529.
23. Akizawa T, Nangaku M, Yamaguchi T, Koretomo R, Maeda K, Yamada O, Hirakata H. Two long-term phase 3 studies of enarodustat (JTZ-951) in Japanese anemic patients with chronic kidney disease not on dialysis or on maintenance hemodialysis: SYMPHONY ND-Long and HD-Long studies. *Ther Apher Dial*. 2022 Apr;26(2):345-356.
24. Akizawa T, Nobori K, Matsuda Y, Taki K, Hayashi Y, Hayasaki T, Yamamoto H. Molidustat for the treatment of anemia in Japanese patients undergoing peritoneal dialysis: a single-arm, open-label, phase 3 study. *Ther Apher Dial*. 2022 Apr;26(2):368-377.
25. Muso E, Sakai S, Ogura Y, Yukawa S, Nishizawa Y, Yorioka N, Saito T, Mune M, Sugiyama S, Iino Y, Hirano T, Hattori M, Watanabe T, Yokoyama H, Sato H, Uchida S, Wada T, Shoji T, Oda H, Mori K, Kimura H, Ito O, Nishiyama A, Maruyama S, Inagi R, Fujimoto S, Tsukamoto T, Suzuki Y, Honda H, Babazono T, Tsuruya K, Yuzawa Y. Favorable therapeutic efficacy of low-density lipoprotein apheresis for nephrotic syndrome with impaired renal function. *Ther Apher Dial*. 2022 Feb;26(1):220-228.

■書籍・総説

1. 本田 浩一. 【腎性貧血:HIF-PH 阻害薬への期待と課題】HIF-PH 阻害薬治療と貧血・鉄代謝マーカーの管理基準 鉄代謝マーカーの評価と使い方. 腎と透析(0385-2156)93 巻 2 号 Page217-222(2022. 08).
2. 本田 浩一. 【腎性貧血:HIF-PH 阻害薬への期待と課題】序文. 腎と透析(0385-2156)93 巻 2 号 Page155-157(2022. 08).
3. 本田 浩一. 赤血球造血因子製剤と低酸素誘導因子水酸化酵素阻害薬の使い分け. 日本透析医学会雑誌(1340-3451)55 巻 6 号 Page365-369(2022. 06).
4. 本田 浩一. 【腎代替療法のすべて】(第 9 章)透析患者の合併症 鉄欠乏性貧血・鉄利用障害. 腎と透析(0385-2156)92 巻増刊 Page540-543(2022. 06).
5. 本田 浩一. 腎性貧血治療薬の使い分け. 日本透析医会雑誌(0914-7136)37 巻 1 号 Page69-74(2022. 04).
6. 本田 浩一. 糖尿病性腎臓病患者における HIF-PH 阻害薬. 腎臓内科(2435-1903)15 巻 1 号 Page78-84(2022. 01).
7. 本田 浩一, 吉田 峻祐. 腎性貧血治療薬の使い分け(解説). 日本透析医会雑誌(0914-7136)37 巻 1 号 Page69-74(2022. 04).

【2021 年】

■原著

1. Akizawa T. Appreciation for the contribution of the Japanese Society for Dialysis Therapy to development of Therapeutic Apheresis and Dialysis. Ther Apher Dial. 2021 Dec;25(6):726
2. Akizawa T, Nobori K, Matsuda Y, Hayashi Y, Hayasaki T, Yamamoto H. Molidustat for anemia correction in Japanese patients undergoing hemodialysis: a single-arm, phase 3 study. Ther Apher Dial. 2021 Dec;25(6):917-925
3. Inaba M, Une Y, Ikejiri K, Kanda H, Fukagawa M, Akizawa T. Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan-A Phase 2 Randomized Trial. Kidney Int Rep. 2021 Nov 24;7(2):177-188
4. Yamamoto H, Nobori K, Matsuda Y, Hayashi Y, Hayasaki T, Akizawa T. Letter in Response to "HIF-Prolyl Hydroxylase Inhibitors: Confirmed Efficacy with Uncertain Safety". Am J Nephrol. 2021 Nov 2:1-2
5. Wada Y, Iyoda M, Suzuki T, Tachibana S, Kanazawa N, Matsumoto K, Honda H. Immunopathological analysis of the expression of glomerular exostosin 1 and exostosin 2 in Japanese patients with lupus nephritis. Virchows Arch. 2021 Nov;479(5):997-1005

6. Hasegawa T, Noma H, Hamano T, Abe M, Wada A, Honda H, Ito Y, Masakane I, Nitta K. Association between the use of exchange devices for peritoneal dialysis fluids and peritonitis incidence: A nationwide cohort study. *Perit Dial Int.* 2021 Oct 18;8968608211051591. Online ahead of print
7. Onozawa S, Kimura T, Ito Y, Akizawa T. Estimating the causal effect of transient anemia status on renal and cardiovascular outcomes in community- dwelling patients in Japan at the beginning of impaired renal function using marginal structural modeling. *Clin Exp Nephrol.* 2021 Oct 1
8. Akizawa T, Yamaguchi Y, Majikawa Y, Reusch M. Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients. *Ther Apher Dial.* 2021 Oct;25(5):575-585
9. Koiwa F, Tokunaga S, Asada S, Endo Y, Fukagawa M, Akizawa T. Corrigendum to "Efficacy of evocalcet in previously cinacalcet-treated secondary hyperparathyroidism patients," *Kidney Int Rep.* 2021 Aug 23;6(11):2830-2839
10. Koiwa F, Tokunaga S, Asada S, Endo Y, Fukagawa M, Akizawa T. Efficacy of Evocalcet in Previously Cinacalcet-Treated Secondary Hyperparathyroidism Patients. *Kidney Int Rep.* 2021 Aug 23;6(11):2830-2839
11. Akizawa T, Yamada T, Nobori K, Matsuda Y, Hayashi Y, Hayasaki T, Yamamoto H. Molidustat for Japanese Patients With Renal Anemia Receiving Dialysis. *Kidney Int Rep.* 2021 Jul 23;6(10):2604-2616
12. Akizawa T, Sato Y, Ikejiri K, Kanda H, Fukagawa M. Effect of Tenapanor on Phosphate Binder Pill Burden in Hemodialysis Patients. *Kidney Int Rep.* 2021 Jul 8;6(9):2371-2380
13. Akizawa T, Nangaku M, Yamaguchi T, Koretomo R, Maeda K, Miyazawa Y, Hirakata H. A Phase 3 Study of Enarodustat (JTZ-951) in Japanese Hemodialysis Patients for Treatment of Anemia in Chronic Kidney Disease: SYMPHONY HD Study. *Kidney Dis(Basel).* 2021 Jul 5;7(6):494-502
14. Shikida Y, Mizobuchi M, Yoshitake O, Kato T, Ogata H, Koiwa F, Honda H. Lower soluble Klotho levels in the pretransplant period are associated with an increased risk of renal function decline in renal transplant patients. *Ther Apher Dial.* 2021 Jun;25(3):331-340
15. Iseri K, Carrero JJ, Evans M, Runesson B, Stenvinkel P, Lindholm B, Berg HE, Felländer-Tsai L, Qureshi AR. Secular trends in hip fracture incidence and subsequent mortality in dialysis patients and the general population in Sweden. *Bone.* 2021 Jun;147:115909
16. Ogata H, Shimofurutani N, Okada T, Nagamoto H, Akizawa T. Efficacy and safety of oral tolvaptan in patients undergoing hemodialysis: a Phase 2, double- blind, randomized, placebo-controlled trial. *Nephrol Dial Transplant.* 2021 May 27;36(6):1088-1097

17. Hara T, Kimachi M, Akizawa T, Fukuhara S, Yamamoto Y. Erratum: Interdialytic Weight Gain Effects on Hemoglobin Concentration and Cardiovascular Events. *Kidney Int Rep.* 2021 May 20;6(7):1999-2007
18. Ogata H, Fukagawa M, Hirakata H, Kagimura T, Fukushima M, Akizawa T; LANDMARK Investigators and Committees. Effect of Treating Hyperphosphatemia With Lanthanum Carbonate vs Calcium Carbonate on Cardiovascular Events in Patients With Chronic Kidney Disease Undergoing Hemodialysis: The LANDMARK Randomized Clinical Trial. *JAMA.* 2021 May 18;325(19):1946-1954
19. Akizawa T, Nangaku M, Yamaguchi T, Koretomo R, Maeda K, Miyazawa Y, Hirakata H. A Phase 3 Study of Enarodustat in Anemic Patients with CKD not Requiring Dialysis: The SYMPHONY ND Study. *Kidney Int Rep.* 2021 May 12;6(7):1840-1849
20. Akizawa T, Iwasaki M, Otsuka T, Yamaguchi Y, Reusch M. Phase 3 Study of Roxadustat to Treat Anemia in Non-Dialysis-Dependant CKD. *Kidney Int Rep.* 2021 Apr 17;6(7):1810-1828
21. Akizawa T, Iwasaki M, Yamaguchi Y, Majikawa Y, Reusch M. Authors' Reply. *J Am Soc Nephrol.* 2021 Mar 1;32(4):1005-7
22. Iseri K, Qureshi AR, Ripsweiden J, Heimbürger O, Barany P, Bergström IB, Stenvinkel P, Brismar TB, Lindholm B. Sparing effect of peritoneal dialysis vs hemodialysis on BMD changes and its impact on mortality. *J Bone Miner Metab.* 2021 Mar;39(2):260-269
23. Saito T, Mizobuchi M, Miwa Y, Sugiyama M, Mima Y, Iida A, Kanazawa N, Morikawa T, Hayashi J, Fukuda K, Shikida Y, Suzuki T, Honda H. Anti-MDA-5 antibody-positive clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease treated with therapeutic plasma exchange: A case series. *J Clin Apher.* 2021 Feb;36(1):196-205
24. Hayashi T, Kato H, Tanabe K, Nangaku M, Hirakata H, Wada T, Sato H, Yamazaki Y, Masaki T, Kagimura T, Yamamoto H, Hase H, Kamouchi M, Imai E, Mizuno K, Iwasaki M, Akizawa T, Tsubakihara Y, Maruyama S, Narita I. Initial responsiveness to darbepoetin alfa and its contributing factors in non-dialysis chronic kidney disease patients in Japan. *Clin Exp Nephrol.* 2021 Feb;25(2):110-119
25. Saito T, Mizobuchi M, Hamada T, Sugiyama M, Miyazawa M, Morikawa T, Matsumoto K, Yoshitake O, Aoki T, Murakami M, Honda H. Tumoral calcinosis due to severe hyperphosphatemia and secondary hyperparathyroidism without vascular calcification in a hemodialysis patient. *Clin Nephrol.* 2021 Jan 12. Online ahead of print
26. Wada Y, Iyoda M, Matsumoto K, Suzuki T, Tachibana S, Kanazawa N, Honda H. Reno-protective effect of IL-34 inhibition on cisplatin-induced nephrotoxicity in mice. *PLoS One.* 2021 Jan 11;16(1):e0245340

27. Yokoyama K, Fukagawa M, Shigematsu T, Akiba T, Yoshikawa K, Tsuchiya A, Kuwabara M, Akizawa T. Safety and efficacy of etelcalcetide, an intravenous calcimimetic, for up to 52 weeks in hemodialysis patients with secondary hyperparathyroidism: results of a post-marketing surveillance in Japan. *Clin Exp Nephrol*. 2021 Jan;25(1):66-79
28. Wakamatsu T, Iwasaki Y, Yamamoto S, Matsuo K, Goto S, Narita I, Kazama JJ, Tanaka K, Ito A, Ozasa R, Nakano T, Miyakoshi C, Onishi Y, Fukuma S, Fukuhara S, Yamato H, Fukagawa M, Akizawa T. Type I Angiotensin II Receptor Blockade Reduces Uremia-Induced Deterioration of Bone Material Properties. *J Bone Miner Res*. 2021 Jan;36(1):67-79
29. Komatsu N, Akizawa T, Arita K, Mitsui H, Nemoto T, Hanaki K. [The effect of ferric citrate hydrate as an iron replacement therapy in Japanese patients with iron deficiency anemia]. *Rinsho Ketsueki*. 2021;62(11):1583-1592. Japanese
30. Kikuchi K, Nangaku M, Ryuzaki M, Yamakawa T, Yoshihiro O, Hanafusa N, Sakai K, Kanno Y, Ando R, Shinoda T, Nakamoto H, Takemoto Y, Akizawa T; COVID-19 Task Force Committee of the Japanese Association of Dialysis Physicians, the Japanese Society for Dialysis Therapy, and the Japanese Society of Nephrology. Survival and predictive factors in dialysis patients with COVID-19 in Japan: a nationwide cohort study. *Ren Replace Ther*. 2021;7(1):59
31. Akizawa T, Tanaka-Amino K, Otsuka T, Yamaguchi Y. Factors Affecting Doses of Roxadustat Versus Darbepoetin Alfa for Anemia in Nondialysis Patients. *Am J Nephrol*. 2021;52(9):702-713
32. Yamamoto H, Nobori K, Matsuda Y, Hayashi Y, Hayasaki T, Akizawa T. Efficacy and Safety of Molidustat for Anemia in ESA-Naive Nondialysis Patients: A Randomized, Phase 3 Trial. *Am J Nephrol*. 2021;52(10-11):871-883
33. Yamamoto H, Nobori K, Matsuda Y, Hayashi Y, Hayasaki T, Akizawa T. Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study. *Am J Nephrol*. 2021;52(10-11):884-893
34. Shigematsu T, Une Y, Ikejiri K, Kanda H, Fukagawa M, Akizawa T. Therapeutic Effects of Add-On Tenapanor for Hemodialysis Patients with Refractory Hyperphosphatemia. *Am J Nephrol*. 2021;52(6):496-506
35. Nangaku M, Hamano T, Akizawa T, Tsubakihara Y, Nagai R, Okuda N, Kurata K, Nagakubo T, Jones NP, Endo Y, Cobitz AR. Daprodustat Compared with Epoetin Beta Pegol for Anemia in Japanese Patients Not on Dialysis: A 52-Week Randomized Open-Label Phase 3 Trial. *Am J Nephrol*. 2021;52(1):26-35

■書籍・総説

1. 森川 友喜, 本田 浩一. 【腎疾患治療薬 update】(第 2 章)慢性腎臓病・透析合併症 腎性貧血治療薬 鉄剤 クエン酸第二鉄水和物. 腎と透析(0385-2156)91 巻増刊 Page365-370.
2. 齋藤 友広, 本田 浩一. 【腎疾患治療薬 update】(第 2 章)慢性腎臓病・透析合併症 腎性貧血治療薬 鉄剤 経口鉄剤. 腎と透析(0385-2156)91 巻増刊 Page344-348.
3. 本田 浩一. 【腎疾患治療薬 update】(第 2 章)慢性腎臓病・透析合併症 腎性貧血治療薬 HIF-PH阻害薬 ダプロデュスタット腎と透析(0385-2156)91 巻増刊 Page319-324.
4. 溝渕 正英, 齋藤 友広, 本田 浩一. 透析患者における運動器障害と骨粗鬆症薬物治療 CKD-MBD 管理と骨折リスクへの対策. 日本骨粗鬆症学会雑誌(2189-8383)7 巻 2 号 Page382-385.
5. 本田 浩一. 【腎性貧血治療の新展開-HIF-PH 阻害薬への期待-】HIF-PH 阻害薬の特性 HIF-PH阻害薬導入時の注意点 保存期CKD患者の場合. Progress in Medicine(0287-3648)41 巻 5 号 Page461-466.
6. 森川 友喜, 本田 浩一. 【水・電解質を科学する】水・電解質異常の病態と治療 骨代謝と腎臓. 腎と透析(0385-2156)90 巻 5 号 Page855-860.
7. 齋藤 友広, 本田 浩一. 【腎性貧血 update】腎性貧血治療の意義と目標値ガイドラインの国際比較を含めて 保存期 CKD 患者. 腎臓内科(2435-1903)13 巻 5 号 Page579-586.
8. 本田 浩一. 注目の新薬 バフセオ錠(バダデュスタット). 診断と治療(0370-999X)109 巻 5 号 Page703-708.
9. 本田 浩一. 慢性腎臓病 (CKD) 患者の脂質異常. 昭和学会雑誌(2187-719X)80 巻 6 号 Page478-484
10. 池田 美紗, 本田 浩一. 【サルコペニア・フレイルの栄養療法・運動療法】腎機能障害時のサルコペニア・フレイル発症原因 慢性炎症症候群 MIA 症候群・腎性貧血・サイトカイン症候群. 腎と透析(0385-2156)90 巻 3 号 Page377-381
11. 鈴木 泰平, 森川 友喜, 佐藤 望, 神林 由衣, 吉武 理, 本田 浩一. 下腿浮腫と体重増加を呈し精査入院となった生体腎移植後患者の 1 例. 臨床透析(0910-5808)37 巻 1 号 Page89-95.
12. 本田 浩一. 【透析期に適した HIF-PH 阻害薬「ロキサデュスタット」】. Astellas Square: 明日の医療を考える(1880-0319)16 巻 4 号 Page12-18

【2020年】

■原著

1. Iseri K, Carrero JJ, Evans M, Felländer-Tsai L, Berg HE, Runesson B, Stenvinkel P, Lindholm B, Qureshi AR. Incidence of Fractures Before and After Dialysis Initiation. *J Bone Miner Res.* 2020 Dec;35(12):2372-2380
2. Iseri K, Carrero JJ, Evans M, Felländer-Tsai L, Berg HE, Runesson B, Stenvinkel P, Lindholm B, Qureshi AR. Fractures after kidney transplantation: Incidence, predictors, and association with mortality. *Bone.* 2020 Nov;140:115554
3. Kato T, Mizobuchi M, Sasa K, Yamada A, Ogata H, Honda H, Sakashita A, Kamijo R. Osteoblastic differentiation of bone marrow mesenchymal stem cells in uremic rats. *Biochem Biophys Res Commun.* 2020 Oct 29;532(1):11-18
4. Kato C, Fujii N, Miyakoshi C, Asada S, Onishi Y, Fukuma S, Nomura T, Wada M, Fukagawa M, Fukuhara S, Akizawa T. Changes in 3-month mineral and bone disorder patterns were associated with all-cause mortality in prevalent hemodialysis patients with secondary hyperparathyroidism. *BMC Nephrol.* 2020 Oct 12;21(1):432
5. Honda H, Kimachi M, Kurita N, Joki N, Nangaku M. Low rather than high mean corpuscular volume is associated with mortality in Japanese patients under hemodialysis. *Sci Rep.* 2020 Sep 24;10(1):15663
6. Akizawa T, Nangaku M, Yonekawa T, Okuda N, Kawamatsu S, Onoue T, Endo Y, Hara K, Cobitz AR. Efficacy and Safety of Daprodustat Compared with Darbepoetin Alfa in Japanese Hemodialysis Patients with Anemia: A Randomized, Double-Blind, Phase 3 Trial. *Clin J Am Soc Nephrol.* 2020 Aug 7;15(8):1155-1165
7. Kanazawa N, Wada Y, Akiyama M, Shikida Y, Sugiyama M, Abe M, Iyoda M, Honda K, Shibata T. Crescentic IgA nephropathy after administration of human monoclonal interleukin-12/23p40 antibody in a patient with Crohn's disease: a case report. *CEN Case Rep.* 2020 Aug;9(3):204-209
8. Shigematsu T, Fukagawa M, Yokoyama K, Akiba T, Fujii A, Shinoda A, Akizawa T. Influence of dialysate Ca concentrations on the therapeutic effects of etelcalcetide with concomitant drugs in patients with secondary hyperparathyroidism. *Nephrology (Carlton).* 2020 Aug;25(8):634-643
9. Hara T, Kimachi M, Akizawa T, Fukuhara S, Yamamoto Y. Interdialytic Weight Gain Effects on Hemoglobin Concentration and Cardiovascular Events. *Kidney Int Rep.* 2020 Jul 27;5(10):1670-1678
10. Asada S, Yokoyama K, Miyakoshi C, Fukuma S, Endo Y, Wada M, Nomura T, Onishi Y, Fukagawa M, Fukuhara S, Akizawa T. Relationship between serum calcium or phosphate levels

and mortality stratified by parathyroid hormone level: an analysis from the MBD-5D study. *Clin Exp Nephrol.* 2020 Jul;24(7):630-637

11. Honda H, Tanaka K, Michihata T, Shibagaki K, Yuza T, Hirao K, Tomosugi N, Ganz T, Higashimoto Y. Erythropoiesis stimulating agents are associated with serum fibroblast growth factor 23 metabolism in patients on hemodialysis. *Clin Kidney J.* 2020 Jun 23;14(3):943-949

12. Shigematsu T, Asada S, Endo Y, Kawata T, Fukagawa M, Akizawa T. Efficacy and Safety of Evocalcet Evaluated by Dialysate Calcium Concentration in Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis. *Int J Nephrol Renovasc Dis.* 2020 May 12;13:97-106

13. Hayashi T, Maruyama S, Nangaku M, Narita I, Hirakata H, Tanabe K, Morita S, Tsubakihara Y, Imai E, Akizawa T; PREDICT Investigators. Darbepoetin Alfa in Patients with Advanced CKD without Diabetes: Randomized, Controlled Trial. *Clin J Am Soc Nephrol.* 2020 May 7;15(5):608-615

14. Saito T, Mima Y, Sugiyama M, Miyazawa N, Iida A, Kanazawa N, Suzuki T, Shikida Y, Hamada T, Wada Y, Mizobuchi M, Honda H. Multidisciplinary management of calciphylaxis: a series of 5 patients at a single facility. *CEN Case Rep.* 2020 May;9(2):122-128

15. Sugiyama M, Wada Y, Kanazawa N, Tachibana S, Suzuki T, Matsumoto K, Iyoda M, Honda H, Shibata T. A cross-sectional analysis of clinicopathologic similarities and differences between Henoch-Schönlein purpura nephritis and IgA nephropathy. *PLoS One.* 2020 Apr 23;15(4):e0232194

16. Nangaku M, Kanda H, Takama H, Ichikawa T, Hase H, Akizawa T. Randomized Clinical Trial on the Effect of Bardoxolone Methyl on GFR in Diabetic Kidney Disease Patients (TSUBAKI Study). *Kidney Int Rep.* 2020 Apr 14;5(6):879-890

17. Iseri K, Carrero JJ, Evans M, Felländer-Tsai L, Berg H, Runesson B, Stenvinkel P, Lindholm B, Qureshi AR. Major fractures after initiation of dialysis: Incidence, predictors and association with mortality. *Bone.* 2020 Apr;133:115242

18. Kawata N, Kang D, Aiuchi T, Obama T, Yoshitake O, Shibata T, Takimoto M, Itabe H, Honda K. Proteomics of human glomerulonephritis by laser microdissection and liquid chromatography-tandem mass spectrometry. *Nephrology (Carlton).* 2020 Apr;25(4):351-359

19. Karaboyas A, Morgenstern H, Fleischer NL, Vanholder RC, Dhalwani NN, Schaeffner E, Schaubel DE, Akizawa T, James G, Sinsakul MV, Pisoni RL, Robinson BM. Inflammation and Erythropoiesis-Stimulating Agent Response in Hemodialysis Patients: A Self-matched Longitudinal Study of Anemia Management in the Dialysis Outcomes and Practice Patterns Study (DOPPS). *Kidney Med.* 2020 Mar 26;2(3):286-296

20. Mizobuchi M, Ogata H, Koiwa F, Honda H. Early response of the parathyroid gland to withdrawal of a calcimimetic compound in uremic rats. *Am J Physiol Renal Physiol.* 2020 Mar

1;318(3):F639-F646

21. Kamitani T, Fukuma S, Shimizu S, Akizawa T, Fukuhara S. Length of hospital stay is associated with a decline in activities of daily living in hemodialysis patients: a prospective cohort study. *BMC Nephrol.* 2020 Jan 8;21(1):9
22. Iseri K, Qureshi AR, Dai L, Ripsweiden J, Heimbürger O, Barany P, Bergström I, Stenvinkel P, Brismar TB, Lindholm B. Bone mineral density at different sites and 5 years mortality in end-stage renal disease patients: A cohort study. *Bone.* 2020 Jan;130:115075
23. Tschiderer L, Seekircher L, Klingenschmid G, Izzo R, Baldassarre D, Iglseider B, Calabresi L, Liu J, Price JF, Bae JH, Brouwers FP, de Groot E, Schmidt C, Bergström G, Aşçi G, Gresele P, Okazaki S, Kapellas K, Landecho MF, Sattar N, Agewall S, Zou ZY, Byrne CD, Nanayakkara PWB, Papagianni A, Witham MD, Bernal E, Ekart R, van Agtmael MA, Neves MF, Sato E, Ezhov M, Walters M, Olsen MH, Stolić R, Zozulińska-Ziółkiewicz DA, Hanefeld M, Staub D, Nagai M, Nieuwkerk PT, Huisman MV, Kato A, Honda H, Parraga G, Magliano D, Gabriel R, Rundek T, Espeland MA, Kiechl S, Willeit J, Lind L, Empana JP, Lonn E, Tuomainen TP, Catapano A, Chien KL, Sander D, Kavousi M, Beulens JWJ, Bots ML, Sweeting MJ, Lorenz MW, Willeit P; Proof-ATHERO Study Group. The Prospective Studies of Atherosclerosis (Proof-ATHERO) Consortium: Design and Rationale. *Gerontology.* 2020;66(5):447-459
24. Akizawa T, Yamaguchi Y, Otsuka T, Reusch M. A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naïve Chronic Kidney Disease Patients Not on Dialysis. *Nephron.* 2020;144(8):372-382
25. Kanazawa N, Iyoda M, Tachibana S, Matsumoto K, Wada Y, Suzuki T, Iseri K, Shibata T. Therapeutic Potential of Thrombomodulin in Renal Fibrosis of Nephrotoxic Serum Nephritis in Wistar-Kyoto Rats. *Kidney Blood Press Res.* 2020;45(3):391-406
26. 溝渕正英. Vascular health に対する VDRA 作用の可能性(原著論文). 日本透析医学会雑誌 (0914-7136)35 卷 2 号 Page434-437(2020.08)

■ 書籍・総説

1. Iseri K, Dai L, Chen Z, Qureshi AR, Brismar TB, Stenvinkel P, Lindholm B. Bone mineral density and mortality in end-stage renal disease patients. *Clin Kidney J.* 2020 Jun 26;13(3):307-321.
2. COVID-19 Task Force Committee of the Japanese Association of Dialysis Physicians; Japanese Society for Dialysis Therapy; Japanese Society of Nephrology, Kikuchi K, Nangaku M, Ryuzaki M, Yamakawa T, Hanafusa N, Sakai K, Kanno Y, Ando R, Shinoda T, Nakamoto H, Akizawa T. COVID-19 of dialysis patients in Japan: Current status and guidance on preventive measures. *Ther Apher Dial.* 2020

Aug;24(4):361-365.

3. 金澤 伸洋, 本田 一穂. 【腎疾患コンサルテーション】画像診断関連 腎生検が有用な疾患と禁忌(解説/特集). 腎と透析 (0385-2156)89 巻 4 号 Page502-505(2020. 10)
4. 溝渕 正英. 【腎疾患コンサルテーション】生化学異常、電解質異常 Ca 濃度異常の鑑別診断と対応(解説/特集). 腎と透析 (0385-2156)89 巻 4 号 Page466-469(2020. 10)
5. 鈴木 泰平, 本田 一穂. 【腎臓の構成細胞から再考する:基礎と臨床】足細胞(ポウマン嚢臓側上皮細胞) 足細胞の解剖学的特徴と機能分子(解説/特集). 腎と透析 (0385-2156)89 巻 3 号 Page351-359(2020. 09)
6. 本田 浩一, 森川 友喜. 【腎性貧血 revisit】エリスロフェン(解説/特集). 腎と透析 (0385-2156)89 巻 2 号 Page251-255(2020. 08)
7. 秋澤 忠男, 横地 章生. 【腎性貧血 revisit】新しい腎性貧血治療薬 HIF-PHI Enarodustat(解説/特集). 腎と透析 (0385-2156)89 巻 2 号 Page217-222(2020. 08)
8. 本田 浩一. 【透析療法の課題と展望 2020】水溶性ビタミンの補充(解説/特集). 腎と透析 (0385-2156)88 巻 5 号 Page683-687(2020. 05)
9. 本田 浩一. 話題・論点 新型コロナウイルス(解説). 臨床透析 (0910-5808)36 巻 4 号 Page399-400(2020. 04)
10. 本田 浩一. 【世間の荒波にもまれる CKD-MBD 治療】CKD-MBD の治療 PTH 低下薬 calcimimetics を中心に(解説/特集). 臨床透析 (0910-5808)36 巻 4 号 Page347-355(2020. 04)
11. 本田 浩一. 血液透析患者における腎性貧血治療と鉄代謝、FGF23 との関係(解説)
12. 本田 浩一, 田中 賢治, 平尾 圭市, 柴垣 圭吾, 油座 利貴, 道端 哲郎, 友杉 直久, Ganz Tomas, 東元 祐一郎. 日本透析医会雑誌 (0914-7136)35 巻 1 号 Page210-213(2020. 04)
13. 溝渕 正英, 齋藤 友広. 【CKD-MBD up to date】治療薬の進歩 カルシウム感知受容体作動薬(解説/特集). 腎と透析 (0385-2156)88 巻 1 号 Page68-71(2020. 01)
14. 柴田 孝則. 免疫病理学的視点と糸球体疾患(解説). 昭和学士会雑誌 (2187-719X)79 巻 4 号 Page437-440(2019. 08)

【2019年】

■原著

1. Wada Y, Gonzalez-Sanchez HM, Weinmann-Menke J, Iwata Y, Ajay AK, Meineck M, Kelley VR. IL-34-Dependent Intrarenal and Systemic Mechanisms Promote Lupus Nephritis in MRL-Faslpr Mice. *J Am Soc Nephrol*. 2019 Feb;30(2):244-259.
2. Hara T, Kimachi M, Ikenoue T, Akizawa T, Fukuhara S, Yamamoto Y. Intra-Dialytic Hemoglobin Changes and Cardiovascular Events: A Cohort Study on Dialysis Outcomes and Practice Patterns in Japan. *Am J Nephrol*. 2019;50(4):272-280.
3. Dai L, Watanabe M, Qureshi AR, Mukai H, Machowska A, Heimbürger O, Barany P, Lindholm B, Stenvinkel P. Serum 8-hydroxydeoxyguanosine, a marker of oxidative DNA damage, is associated with mortality independent of inflammation in chronic kidney disease. *Eur J Intern Med*. 2019 Oct;68:60-65.
4. Akizawa T, Macdougall IC, Berns JS, Yamamoto H, Taguchi M, Iekushi K, Bernhardt T. Iron Regulation by Molidustat, a Daily Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, in Patients with Chronic Kidney Disease. *Nephron*. 2019;143(4):243-254.
5. Fukuma S, Fukuhara S, Shimizu S, Akizawa T, Fukagawa M. Population-level associations of achievement of targets for bone-mineral markers with survival in haemodialysis patients with mildly elevated intact-PTH levels: a case-cohort study. *Sci Rep*. 2019 Aug 5;9(1):11301.
6. Runesson B, Trevisan M, Iseri K, Qureshi AR, Lindholm B, Barany P, Elinder CG, Carrero JJ. Fractures and their sequelae in non-dialysis-dependent chronic kidney disease: the Stockholm CREATinine Measurement project. *Nephrol Dial Transplant*. 2020 Nov 1;35(11):1908-1915.
7. Iseri K, Watanabe M, Lee XP, Yamada M, Ryu K, Iyoda M, Uchida N, Sato K, Shibata T. Elimination of intravenous alendronate by hemodialysis: A kinetic study. *Hemodial Int*. 2019 Oct;23(4):466-471.
8. Tsuruya K, Shimazaki R, Fukagawa M, Akizawa T; Evocalcet Study Group. Correction to: Efficacy and safety of evocalcet in Japanese peritoneal dialysis patients. *Clin Exp Nephrol*. 2019 Sep;23(9):1173.
9. Yamamoto H, Taguchi M, Matsuda Y, Iekushi K, Yamada T, Akizawa T. Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies. *BMJ Open*. 2019 Jun 14;9(6):e026704.
10. Akizawa T, Taguchi M, Matsuda Y, Iekushi K, Yamada T, Yamamoto H. Molidustat

for the treatment of renal anaemia in patients with dialysis-dependent chronic kidney disease: design and rationale of three phase III studies. *BMJ Open*. 2019 Jun 14;9(6):e026602.

11. Akizawa T, Nangaku M, Yamaguchi T, Arai M, Koretomo R, Maeda K, Miyazawa Y, Hirakata H. Enarodustat, Conversion and Maintenance Therapy for Anemia in Hemodialysis Patients: A Randomized, Placebo-Controlled Phase 2b Trial Followed by Long-Term Trial. *Nephron*. 2019;143(2):77-85.
12. Ohnishi T, Kimachi M, Fukuma S, Akizawa T, Fukuhara S. Postdialysis Hypokalemia and All-Cause Mortality in Patients Undergoing Maintenance Hemodialysis. *Clin J Am Soc Nephrol*. 2019 Jun 7;14(6):873-881.
13. Iida A, Wada Y, Hayashi J, Tachibana S, Inaba T, Iyoda M, Honda K, Shibata T. Membranous nephropathy caused by rheumatoid arthritis. *CEN Case Rep*. 2019 Nov;8(4):233-238.
14. Yokoyama K, Shimazaki R, Fukagawa M, Akizawa T; Evocalcet Study Group. Long-Term Efficacy and Safety of Evocalcet in Japanese Patients with Secondary Hyperparathyroidism Receiving Hemodialysis. *Sci Rep*. 2019 Apr 23;9(1):6410. doi: 10.1038/s41598-019-42017-z. PMID: 31015494; PMCID: PMC6478860.
15. Koiwa F, Yokoyama K, Fukagawa M, Akizawa T. Evaluation of changes in ferritin levels during sucroferriic oxyhydroxide treatment. *Clin Kidney J*. 2018 Sep 19;12(2):294-299.
16. Iimuro S, Kaneko T, Ohashi Y, Watanabe T, Nitta K, Akizawa T, Matsuo S, Imai E, Makino H, Hishida A; CKD-JAC Investigators. Analysis of 2897 hospitalization events for patients with chronic kidney disease: results from CKD-JAC study. *Clin Exp Nephrol*. 2019 Jul;23(7):956-968.
17. Tsuruya K, Shimazaki R, Fukagawa M, Akizawa T; Evocalcet Study Group. Efficacy and safety of evocalcet in Japanese peritoneal dialysis patients. *Clin Exp Nephrol*. 2019 Jun;23(6):739-748. doi: 10.1007/s10157-019-01692-y. Epub 2019 Apr 6. Erratum in: *Clin Exp Nephrol*. 2019 Jul 5;:
18. Akizawa T, Macdougall IC, Berns JS, Bernhardt T, Staedtler G, Taguchi M, Iekushi K, Krueger T. Long-Term Efficacy and Safety of Molidustat for Anemia in Chronic Kidney Disease: DIALOGUE Extension Studies. *Am J Nephrol*. 2019;49(4):271-280.
19. Akizawa T, Nangaku M, Yamaguchi T, Arai M, Koretomo R, Matsui A, Hirakata H. A Placebo-Controlled, Randomized Trial of Enarodustat in Patients with Chronic Kidney Disease Followed by Long-Term Trial. *Am J Nephrol*. 2019;49(2):165-174.
20. Iseri K, Watanabe M, Yoshikawa H, Mitsui H, Endo T, Yamamoto Y, Iyoda M, Ryu

- K, Inaba T, Shibata T. Effects of Denosumab and Alendronate on Bone Health and Vascular Function in Hemodialysis Patients: A Randomized, Controlled Trial. *J Bone Miner Res.* 2019 Jun;34(6):1014-1024.
21. Akizawa T, Shimazaki R, Shiramoto M, Fukagawa M; Evocalcet Study Group. Response to Comments on "Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study". *Clin Drug Investig.* 2019 Jan;39(1):109-111.
 22. Mima Y, Wada Y, Shikida Y, Hamada T, Kanazawa N, Iida A, Sugiyama M, Shibata T. Rapid regression of calciphylaxis in a hemodialysis patient after intensive management of disturbance of calcium and phosphate metabolism: a case report with literature review. *Renal Replacement Therapy* 2019;5:19
 23. 松本 啓, 金澤 伸洋, 鈴木 泰平, 森川 友喜, 稲葉 大朗, 伊與田 雅之, 山宮 知, 坂木 理, 吉田 仁, 柴田 孝則. 胆嚢仮性動脈瘤破裂による胆道出血を呈した維持血液透析患者の 1 例. *日本透析医学会雑誌* (1340-3451)52 巻 3 号 Page185-190(2019. 03)
 24. 稲葉 大朗, 井芹 健, 森川 友喜, 林 純一, 柴田 孝則. 血液透析導入期の transferrin saturation と虚血性心疾患発症との関連(原著論文). *昭和学会雑誌* (2187-719X)79 巻 6 号 Page716-724(2019. 12).
 25. 林 純一, 井芹 健, 稲葉 大朗, 森川 友喜, 柴田 孝則. 感染症を呈した慢性腎臓病患者における生命予後予測のスコアリングモデルの作成と検証(原著論文). *昭和学会雑誌* (2187-719X)79 巻 5 号 Page642-653(2019. 10)
 26. 森川 友喜, 井芹 健, 稲葉 大朗, 林 純一, 柴田 孝則. 血液透析導入期のエリスロポエチン抵抗性指数と導入後の生命予後との関連(原著論文). *昭和学会雑誌* (2187-719X)79 巻 5 号 Page627-635(2019. 10)
 27. 溝渕 正英. 腎不全の血管中膜石灰化における内膜機能の役割(原著論文). *日本透析医学会雑誌* (0914-7136)34 巻 3 号 Page487-490(2019. 12)

■書籍・総説

1. Akizawa T, Ikejiri K, Kondo Y, Endo Y, Fukagawa M. Evocalcet: A New Oral Calcimimetic for Dialysis Patients With Secondary Hyperparathyroidism. *Ther Apher Dial.* 2019 Sep 5;24(3):248-57.
2. 溝渕 正英, 緒方 浩顕, 小岩 文彦. Dialysis therapy、2018 year in review CKD-MBD(解説). *日本透析医学会雑誌* (1340-3451)52 巻 12 号 Page776-777(2019. 12)
3. 金澤 伸洋, 本田 一穂. 【腎生検から病因と病態を読む】電子顕微鏡と蛍光

- 抗体法から病因と病態を考える(解説/特集). 腎と透析 (0385-2156)87 巻 4 号 Page559-566 (2019. 10)
4. 本田 浩一. 【全身性疾患と腎 update】(第 8 章)電解質異常 高カルシウム血症・腎臓専門医の視点より(解説/特集). 腎と透析 (0385-2156)86 巻増刊 Page471-473 (2019. 06)
 5. 本田 浩一, 田中 賢治, 平尾 圭市, 柴垣 圭吾, 油座 利貴, 道端 哲郎, 友杉 直久, 本宮 善恢, 柴田 孝則. 血液透析患者における腎性貧血治療と鉄代謝・FGF23 との関係(解説). 日本透析医学会雑誌 (0914-7136)34 巻 1 号 Page128-130 (2019. 04)
 6. 本田浩一. 【高リン血症の新たなアプローチ-特性から考えるスクロオキシ水酸化鉄の可能性】スクロオキシ水酸化鉄の位置づけ(解説/特集). 腎・高血圧の最新治療 (2187-0004)8 巻 1 号 Page32-37 (2019. 01)

【2018 年】

■原著

1. Nishiwaki H, Fukuma S, Hasegawa T, Kimachi M, Akizawa T, Fukuhara S. Dialysis-related practice patterns among hemodialysis patients with cancer. *Health Sci Rep*. 2018 May 16;1(7):e46.
2. Macdougall IC, Akizawa T, Berns JS, Bernhardt T, Krueger T. Effects of Molidustat in the Treatment of Anemia in CKD. *Clin J Am Soc Nephrol*. 2019 Jan 7;14(1):28-39.
3. Kurita N, Akizawa T, Fukuhara S. Vitality Measured as Self-reported Energy Level and Clinical Outcomes in Hemodialysis Patients: The Japanese Dialysis Outcomes and Practice Pattern Study (J-DOPPS). *Am J Kidney Dis*. 2019 Apr;73(4):486-495.
4. Shigematsu T, Fukagawa M, Yokoyama K, Akiba T, Fujii A, Odani M, Akizawa T. Effects of the Intravenous Calcimimetic Etelcalcetide on Bone Turnover and Serum Fibroblast Growth Factor 23: Post Hoc Analysis of an Open-label Study. *Clin Ther*. 2018 Dec;40(12):2099-2111.
5. Wada Y, Matsumoto K, Suzuki T, Saito T, Kanazawa N, Tachibana S, Iseri K, Sugiyama M, Iyoda M, Shibata T. Clinical significance of serum and mesangial galactose-deficient IgA1 in patients with IgA nephropathy. *PLoS One*. 2018 Nov 2;13(11):e0206865.
6. Akizawa T, Shimazaki R, Fukagawa M; Evocalcet Study Group. Phase 2b study of evocalcet (KHK7580), a novel calcimimetic, in Japanese patients with secondary hyperparathyroidism undergoing hemodialysis: A randomized, double-blind, placebo-controlled, dose-finding study. *PLoS One*. 2018 Oct 31;13(10):e0204896.

7. Takahashi G, Honda H, Takahashi K, Ikeda M, Hosaka N, Ogata H, Koiwa F, Shishido K, Shibata T. Truncal Adiposity Influences High-Density Lipoprotein Cholesterol Levels and Cardiovascular Events in Hemodialysis Patients. *J Ren Nutr*. 2019 May;29(3):235-242.
8. Baek JH, Gomez IG, Wada Y, Roach A, Mahad D, Duffield JS. Deletion of the Mitochondrial Complex-IV Cofactor Heme A:Farnesyltransferase Causes Focal Segmental Glomerulosclerosis and Interferon Response. *Am J Pathol*. 2018 Dec;188(12):2745-2762.
9. Shigematsu T, Shimazaki R, Fukagawa M, Akizawa T. Pharmacokinetics of evocalcet in secondary hyperparathyroidism patients receiving hemodialysis: first-in-patient clinical trial in Japan. *Clin Pharmacol*. 2018 Sep 11;10:101-111.
10. Narushima K, Maeda H, Shiramoto M, Endo Y, Ohtsuka S, Nakamura H, Nagata Y, Uchimura T, Kannami A, Shimazaki R, Fukagawa M, Akizawa T. Assessment of CYP-Mediated Drug Interactions for Evocalcet, a New Calcimimetic Agent, Based on In Vitro Investigations and a Cocktail Study in Humans. *Clin Transl Sci*. 2019 Jan;12(1):20-27.
11. Akizawa T, Shimazaki R, Shiramoto M, Fukagawa M; Evocalcet Study Group. Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study. *Clin Drug Investig*. 2018 Oct;38(10):945-954.
12. Shigematsu T, Shimazaki R, Fukagawa M, Akizawa T; Evocalcet Study Group. Pharmacodynamics of evocalcet for secondary hyperparathyroidism in Japanese hemodialysis patients. *Clin Exp Nephrol*. 2019 Feb;23(2):258-267.
13. Shimizu S, Fukuma S, Ikenoue T, Akizawa T, Fukuhara S. Increased Mortality Rate after Hospitalization Among Chronic Hemodialysis Patients: A Prospective Cohort Study. *Nephron*. 2018;140(3):194-202. doi: 10.1159/000492083. Epub 2018 Aug 28. PMID: 30153677.
14. Fukuma S, Kimachi M, Omae K, Kataoka Y, Yamazaki H, Muto M, Akizawa T, Yanagita M, Fukuhara S. Dialysis physicians' referral behaviors for hemodialysis patients suspected of having cancer: A vignette-based questionnaire study. *PLoS One*. 2018 Aug 15;13(8):e0202322.
15. Nitta K, Iimuro S, Imai E, Matsuo S, Makino H, Akizawa T, Watanabe T, Ohashi Y, Hishida A. Correction to: Risk factors for increased left ventricular hypertrophy in patients with chronic kidney disease: findings from the CKD-JAC study. *Clin Exp Nephrol*. 2019 Jan;23(1):99.
16. Hasegawa T, Sakamaki K, Koiwa F, Akizawa T, Hishida A; CKD-JAC Study

- Investigators. Clinical prediction models for progression of chronic kidney disease to end-stage kidney failure under pre-dialysis nephrology care: results from the Chronic Kidney Disease Japan Cohort Study. *Clin Exp Nephrol*. 2019 Feb;23(2):189-198.
17. Akizawa T, Kuno Y, Kato N. [Fragility Fractures in Hemodialysis Patients. Uremic bone disease:the effect of medical treatment until now.]. *Clin Calcium*. 2018;28(8):1045-1050. Japanese.
 18. Fukagawa M, Shimazaki R, Akizawa T; Evocalcet study group. Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism. *Kidney Int*. 2018 Oct;94(4):818-825.
 19. Tachibana S, Iyoda M, Matsumoto K, Wada Y, Suzuki T, Iseri K, Kanazawa N, Shibata T. Recombinant human soluble thrombomodulin attenuates anti-glomerular basement membrane glomerulonephritis in Wistar-Kyoto rats through anti-inflammatory effects. *Nephrol Dial Transplant*. 2019 May 1;34(5):774-782.
 20. Nitta K, Iimuro S, Imai E, Matsuo S, Makino H, Akizawa T, Watanabe T, Ohashi Y, Hishida A. Risk factors for increased left ventricular hypertrophy in patients with chronic kidney disease: findings from the CKD-JAC study. *Clin Exp Nephrol*. 2019 Jan;23(1):85-98.
 21. Hoshino J, Larkina M, Karaboyas A, Bieber B, Ubara Y, Takaichi K, Akizawa T, Akiba T, Fukuhara S, Pisoni RL, Saito A, Robinson BM. The Authors Reply. *Kidney Int*. 2018 Jul;94(1):221-222.
 22. Shikida Y, Mizobuchi M, Inoue T, Hamada T, Ogata H, Koiwa F, Shibata T. Effect of Continuous Intravenous Calcium Loading on Fibroblast Growth Factor 23 in Normal and Uremic Rats. *Calcif Tissue Int*. 2018 Oct;103(4):455-464.
 23. Kawata T, Tokunaga S, Murai M, Masuda N, Haruyama W, Shoukei Y, Hisada Y, Yanagida T, Miyazaki H, Wada M, Akizawa T, Fukagawa M. A novel calcimimetic agent, evocalcet (MT-4580/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro. *PLoS One*. 2018 Apr 3;13(4):e0195316.
 24. Iseri K, Iyoda M, Watanabe M, Matsumoto K, Sanada D, Inoue T, Tachibana S, Shibata T. The effects of denosumab and alendronate on glucocorticoid-induced osteoporosis in patients with glomerular disease: A randomized, controlled trial. *PLoS One*. 2018 Mar 15;13(3):e0193846.
 25. Honda H, Ono K, Akizawa T, Nitta K, Hishida A. Correction to: Association of adiposity with hemoglobin levels in patients with chronic kidney disease not on

- dialysis. Clin Exp Nephrol. 2018 Dec;22(6):1476.
26. Sumida K, Yamamoto S, Akizawa T, Fukuhara S, Fukuma S. Body Mass Index Change and Hospitalization Risk in Elderly Hemodialysis Patients: Results from Japanese Dialysis Outcomes and Practice Patterns Study. Am J Nephrol. 2018;47(1):48-56.
 27. 福田 桂[日原], 伊與田 雅之, 齋藤 友広, 荒井 典子[布田], 和田 幸寛, 鈴木 幸恵, 木崎 順一郎, 恩田 秀寿, 高橋 春男, 柴田 孝則. ステロイド抵抗性の抗アクアポリン4抗体陽性視神経炎に対し二重膜濾過血漿交換療法が奏功した1例. 日本透析医学会雑誌 (1340-3451)51 巻 6 号 Page379-385 (2018. 06)
 28. 本田 浩一, 小林 靖奈, 保坂 望, 上竹 大二郎, 有賀 誠記, 柴田 孝則. 血液透析患者における Klotho 遺伝子のメチル化変性と心血管病、栄養障害との関係(原著論文). 日本透析医学会雑誌 (0914-7136)33 巻 2 号 Page325-327 (2018. 08)

■書籍・総説

1. Mizobuchi M, Ogata H, Koiwa F. Secondary Hyperparathyroidism: Pathogenesis and Latest Treatment. Ther Apher Dial. 2019 Aug;23(4):309-318.
2. Okonogi H, Kawamura T, Joh K, Koike K, Miyazaki Y, Ogura M, Tsuboi N, Hirano K, Matsushima M, Yokoo T, Horikoshi S, Suzuki Y, Yasuda T, Shirai S, Shibata T, Hattori M, Akioka Y, Katafuchi R, Hashiguchi A, Hisano S, Shimizu A, Kimura K, Maruyama S, Matsuo S, Tomino Y; Special IgA Nephropathy Study Group. A grading system that predicts the risk of dialysis induction in IgA nephropathy patients based on the combination of the clinical and histological severity. Clin Exp Nephrol. 2019 Jan;23(1):16-25.
3. Akizawa T, Okumura H, Alexandre AF, Fukushima A, Kiyabu G, Dorey J. Burden of Anemia in Chronic Kidney Disease Patients in Japan: A Literature Review. Ther Apher Dial. 2018 Oct;22(5):444-456.
4. Hasegawa T, Koiwa F, Akizawa T. Anemia in conventional hemodialysis: Finding the optimal treatment balance. Semin Dial. 2018 Nov;31(6):599-606.
5. 溝渕 正英, 緒方 浩顕, 小岩 文彦. 【CKD-MBD】CKD-MBD 治療 ビタミンD製剤とカルシウム感受容体作動薬(解説/特集). 日本透析医学会雑誌 (1340-3451)51 巻 11 号 Page681-686 (2018. 11).
6. 本田 浩一. 【検査値の見方を知ってケアに活かす!透析患者の重要検査&検査値 50】(第1章)血液検査 ビタミン B12/葉酸(解説/特集). 透析ケア (1341-1489)2018 冬季増刊 Page107-110 (2018. 12)

7. 溝渕 正英, 加藤 憲. 【水電解質代謝の五角関係】カルシウム/リン代謝の五角関係 トピックス VDRA と vascular health(解説/特集). 腎と透析 (0385-2156)85 巻 3 号 Page457-460(2018. 09)
8. 本田 浩一, 保坂 望. 【骨粗鬆症の Up to date】慢性腎臓病に伴う骨ミネラル代謝異常(CKD-MBD)と骨粗鬆症(解説/特集). 成人病と生活習慣病 (1347-0418)48 巻 9 号 Page1035-1038(2018. 09)
9. 秋澤 忠男, 久野 芳裕, 加藤 徳介. 【透析患者の骨・カルシウム代謝】CKD-MBD 治療の変遷と骨病変(総説/特集). Clinical Calcium (0917-5857)28 巻 8 号 Page1045-1050(2018. 07)
10. 本田 浩一. 【透析医療と合併症 キュア&ケアガイドブック】貧血治療(CQ 38) ESA 低反応性を示す透析患者への対応・対策はどのように行いますか?(解説/特集). 臨床透析 (0910-5808)34 巻 7 号 Page838-841(2018. 06)
11. 本田 浩一, 平野 勉. 【腎と透析ベッドサイド検査事典】(第 8 章)脂質代謝関連物質 β -リポ蛋白、リポ蛋白分画、レムナント様リポ蛋白コレステロール(RLP コレステロール)(解説/特集). 腎と透析 (0385-2156)84 巻増刊 Page244-246(2018. 05)
12. 本田 浩一, 平野 勉. 【腎と透析ベッドサイド検査事典】(第 8 章)脂質代謝関連物質 中性脂肪、遊離脂肪酸(解説/特集). 腎と透析 (0385-2156)84 巻増刊 Page242-243(2018. 05)
13. 本田 浩一, 平野 勉. 【腎と透析ベッドサイド検査事典】(第 8 章)脂質代謝関連物質 総コレステロール、HDL コレステロール、LDL コレステロール、リン脂質(解説/特集). 腎と透析 (0385-2156)84 巻増刊 Page240-241(2018. 05)
14. 式田 康人, 溝渕 正英. 【腎と透析ベッドサイド検査事典】(第 6 章)CKD-MBD 関連検査 リン(解説/特集). 腎と透析 (0385-2156)84 巻増刊 Page186-188(2018. 05)
15. 式田 康人, 溝渕 正英. 【腎と透析ベッドサイド検査事典】(第 6 章)CKD-MBD 関連検査 カルシウム、イオン化カルシウム(解説/特集). 腎と透析 (0385-2156)84 巻増刊 Page184-185(2018. 05)
16. 本田 浩一. 【腎と透析ベッドサイド検査事典】(第 2 章)生化学検査(一般) 低・中分子生化学物質 ペントシジン(解説/特集). 腎と透析 (0385-2156)84 巻増刊 Page62-63(2018. 05)
17. 本田 浩一. 【生活習慣病に必要な水と塩分調節】Ca、P、Mg の調節(解説/特集). 成人病と生活習慣病 (1347-0418)48 巻 3 号 Page270-273(2018. 03)

【2017 年】

■原著

1. Koiwa F, Yokoyama K, Fukagawa M, Akizawa T. Efficacy and Safety of Sucroferric Oxyhydroxide and Calcium Carbonate in Hemodialysis Patients. *Kidney Int Rep.* 2017 Oct 6;3(1):185-192. doi: 10.1016/j.ekir.2017.10.003. PMID: 29340330; PMCID: PMC5762971.
2. Kido R, Akizawa T, Fukagawa M, Onishi Y, Yamaguchi T, Fukuhara S. Interactive Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers or Their Combination on Survival of Hemodialysis Patients. *Am J Nephrol.* 2017;46(6):439-447.
3. Yokoyama K, Fukagawa M, Shigematsu T, Akiba T, Fujii A, Yamauchi A, Odani M, Akizawa T; ONO-5163 Study Group. A Single- and Multiple-Dose, Multicenter Study of Etelcalcetide in Japanese Hemodialysis Patients With Secondary Hyperparathyroidism. *Kidney Int Rep.* 2017 Feb 20;2(4):634-644.
4. Yamada M, Lee XP, Fujishiro M, Iseri K, Watanabe M, Sakamaki H, Uchida N, Matsuyama T, Kumazawa T, Takahashi H, Ishii A, Sato K. Highly sensitive determination of alendronate in human plasma and dialysate using metal-free HPLC-MS/MS. *Leg Med (Tokyo).* 2018 Jan;30:14-20.
5. Honda H, Ono K, Akizawa T, Nitta K, Hishida A. Association of adiposity with hemoglobin levels in patients with chronic kidney disease not on dialysis. *Clin Exp Nephrol.* 2018 Jun;22(3):638-646.
6. Iseri K, Iyoda M, Shikida Y, Inokuchi T, Morikawa T, Hara N, Hirano T, Shibata T. Rituximab for the treatment of type B insulin resistance syndrome: a case report and review of the literature. *Diabet Med.* 2017 Dec;34(12):1788-1791.
7. Yamamoto Y, Iyoda M, Tachibana S, Matsumoto K, Wada Y, Suzuki T, Iseri K, Saito T, Fukuda-Hihara K, Shibata T. Erlotinib attenuates the progression of chronic kidney disease in rats with remnant kidney. *Nephrol Dial Transplant.* 2018 Apr 1;33(4):598-606.
8. Fukuma S, Shimizu S, Shintani A, Kamitani T, Akizawa T, Fukuhara S. Development and validation of a prediction model for loss of physical function in elderly hemodialysis patients. *Nephrol Dial Transplant.* 2018 Aug 1;33(8):1452-1458.
9. Ogata H, Kumasawa J, Fukuma S, Mizobuchi M, Kinugasa E, Fukagawa M, Fukuhara S, Akizawa T. Erratum to: The cardiothoracic ratio and all-cause and cardiovascular disease mortality in patients undergoing maintenance hemodialysis: results of the MBD-5D study. *Clin Exp Nephrol.* 2017 Oct;21(5):809.

10. Kato H, Nangaku M, Hirakata H, Wada T, Hayashi T, Sato H, Yamazaki Y, Masaki T, Kagimura T, Yamamoto H, Hase H, Kamouchi M, Imai E, Mizuno K, Iwasaki M, Akizawa T, Tsubakihara Y, Maruyama S, Narita I. Erratum to: Rationale and design of observational clinical Research In chronic kidney disease patients with renal anemia: renal prognosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetin alfa (BRIGHTEN Trial). *Clin Exp Nephrol*. 2018 Feb;22(1):85-86.
11. Shigematsu T, Fukagawa M, Yokoyama K, Akiba T, Fujii A, Odani M, Akizawa T; ONO-5163 Study Group. Long-term effects of etelcalcetide as intravenous calcimimetic therapy in hemodialysis patients with secondary hyperparathyroidism. *Clin Exp Nephrol*. 2018 Apr;22(2):426-436.
12. Mizobuchi M, Ogata H, Onishi Y, Fukuma S, Akizawa T, Fukuhara S. RAS Inhibitor Is Not Associated With Cardiovascular Benefits in Patients Undergoing Hemodialysis in Japan. *Ther Apher Dial*. 2017 Aug;21(4):326-333.
13. Fukuma S, Ikenoue T, Akizawa T, Fukuhara S. Impact of nutritional index on the association between phosphorus concentrations and mortality in haemodialysis patients: a cohort study from dialysis outcomes and practice pattern study in Japan. *BMJ Open*. 2017 Aug 7;7(8):e016682.
14. Niihata K, Fukuma S, Akizawa T, Fukuhara S. Association of coping strategies with mortality and health-related quality of life in hemodialysis patients: The Japan Dialysis Outcomes and Practice Patterns Study. *PLoS One*. 2017 Jul 25;12(7):e0180498.
15. Ogata H, Kumasawa J, Fukuma S, Mizobuchi M, Kinugasa E, Fukagawa M, Fukuhara S, Akizawa T. Erratum to: The cardiothoracic ratio and all-cause and cardiovascular disease mortality in patients undergoing maintenance hemodialysis: results of the MBD-5D study. *Clin Exp Nephrol*. 2017 Oct;21(5):807-808.
16. Kato H, Nangaku M, Hirakata H, Wada T, Hayashi T, Sato H, Yamazaki Y, Masaki T, Kagimura T, Yamamoto H, Hase H, Kamouchi M, Imai E, Mizuno K, Iwasaki M, Akizawa T, Tsubakihara Y, Maruyama S, Narita I. Rationale and design of observational clinical Research In chronic kidney disease patients with renal anemia: renal prognosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetin alfa (BRIGHTEN Trial). *Clin Exp Nephrol*. 2018 Feb;22(1):78-84.
17. Kurita N, Hayashino Y, Yamazaki S, Akizawa T, Akiba T, Saito A, Fukuhara S. Revisiting Interdialytic Weight Gain and Mortality Association With Serum Albumin Interactions: The Japanese Dialysis Outcomes and Practice Pattern Study. *J*

- Ren Nutr. 2017 Nov;27(6):421-429.
18. Koiwa F, Yokoyama K, Fukagawa M, Akizawa T. Long-Term Assessment of the Safety and Efficacy of PA21 (Sucroferric Oxyhydroxide) in Japanese Hemodialysis Patients With Hyperphosphatemia: An Open-Label, Multicenter, Phase III Study. *J Ren Nutr.* 2017 Sep;27(5):346-354.
 19. Honda H, Hirano T, Ueda M, Kojima S, Mashiba S, Hayase Y, Michihata T, Shishido K, Takahashi K, Hosaka N, Ikeda M, Sanada D, Shibata T. Associations among apolipoproteins, oxidized high-density lipoprotein and cardiovascular events in patients on hemodialysis. *PLoS One.* 2017 May 18;12(5):e0177980.
 20. Ogata H, Kumasawa J, Fukuma S, Mizobuchi M, Kinugasa E, Fukagawa M, Fukuhara S, Akizawa T. The cardiothoracic ratio and all-cause and cardiovascular disease mortality in patients undergoing maintenance hemodialysis: results of the MBD-5D study. *Clin Exp Nephrol.* 2017 Oct;21(5):797-806.
 21. Lipphardt M, Song JW, Matsumoto K, Dadafarin S, Dihazi H, Müller G, Goligorsky MS. The third path of tubulointerstitial fibrosis: aberrant endothelial secretome. *Kidney Int.* 2017 Sep;92(3):558-568.
 22. Hoshino J, Larkina M, Karaboyas A, Bieber BA, Ubara Y, Takaichi K, Akizawa T, Akiba T, Fukuhara S, Pisoni RL, Saito A, Robinson BM. Unique hemoglobin A1c level distribution and its relationship with mortality in diabetic hemodialysis patients. *Kidney Int.* 2017 Aug;92(2):497-503.
 23. Imanishi Y, Fukuma S, Karaboyas A, Robinson BM, Pisoni RL, Nomura T, Akiba T, Akizawa T, Kurokawa K, Saito A, Fukuhara S, Inaba M. Associations of employment status and educational levels with mortality and hospitalization in the dialysis outcomes and practice patterns study in Japan. *PLoS One.* 2017 Mar 6;12(3):e0170731.
 24. Akizawa T, Tsukada J, Kameoka C, Kuroishi K, Yamaguchi Y. Long-Term Safety and Efficacy of Bixalomer in Hyperphosphatemic Patients With Chronic Kidney Disease Not on Dialysis. *Ther Apher Dial.* 2017 Apr;21(2):173-179.
 25. Fukagawa M, Yokoyama K, Shigematsu T, Akiba T, Fujii A, Kuramoto T, Odani M, Akizawa T; ONO-5163 Study Group. A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients. *Nephrol Dial Transplant.* 2017 Oct 1;32(10):1723-1730.
 26. 山本 康隆, 和田 幸寛, 富田 瑛子, 林 純一, 齋藤 友広, 井芹 健, 井上 隆, 柴田 孝則. アスベスト関連疾患を合併し肺高血圧症を呈した腎

不全患者の 1 例. 日本透析医学会雑誌 (1340-3451)50 巻 8 号
Page527-534(2017.08)

27. 溝渕 正英. 透析導入期の心機能評価における心筋核医学検査の有用性
(原著論文). 日本透析医学会雑誌 (0914-7136)31 巻 3 号
Page617-619(2016.12)

■書籍・総説

1. Mizobuchi M, Ogata H, Koiwa F, Kinugasa E, Akizawa T. Research on kidney and mineral metabolism in Japan: past, present, and future. Clin Exp Nephrol. 2017 Mar;21(Suppl 1):4-8.
2. 伊與田 雅之, 橘 翔平, 鈴木 泰平, 柴田 孝則. ウロモジュリンの腎疾患への関与と新規治療薬としての可能性(解説). 細胞 (1346-7557)49 巻 10 号 Page515-519(2017.09)
3. 伊與田 雅之, 橘 翔平, 鈴木 泰平, 柴田 孝則. ウロモジュリンの腎疾患への関与と新規治療薬としての可能性(解説). BIO Clinica (0919-8237)32 巻 5 号 Page512-517(2017.05)
4. 溝渕 正英, 式田 康人. 【CKD 患者におけるリン】CKD 患者におけるリン代謝 CKD 患者の骨代謝異常とリン(解説/特集). 腎と透析 (0385-2156)83 巻 1 号 Page65-68(2017.07)
5. 本田 浩一. 【慢性腎臓病 CKD の合併症対策】CKD の骨折と MBD とその対応(解説 / 特集). 成人病と生活習慣病 (1347-0418)47 巻 6 号 Page713-718(2017.06)
6. 橘 翔平, 和田 幸寛, 伊與田 雅之, 濱田 透眞, 池田 美紗, 山口 裕, 柴田 孝則, 勝馬 愛, 清水 章. 腎生検所見から何を学ぶか(No. 59) 原因診断に苦慮した膜性腎症の 1 例(症例検討会). 腎と透析 (0385-2156)82 巻 3 号 Page447-454(2017.03)

【2016 年】

■原著

1. Hasegawa J, Bieber B, Larkina M, Robinson BM, Wakai S, Akizawa T, Saito A, Fukuhara S, Akiba T. Cardiovascular and Stroke Risk in Japanese Hemodialysis Patients With Atrial Fibrillation. Ther Apher Dial. 2016 Dec;20(6):608-614.
2. Akizawa T, Origasa H, Kameoka C, Tsukada J, Kuroishi K, Yamaguchi Y. Bixalomer in Hyperphosphatemic Patients With Chronic Kidney Disease Not on Dialysis: Phase 3 Randomized Trial. Ther Apher Dial. 2016 Dec;20(6):588-597.
3. Ikeda M, Honda H, Takahashi K, Shishido K, Shibata T. N-Terminal Pro-B-Type

- Natriuretic Peptide as a Biomarker for Loss of Muscle Mass in Prevalent Hemodialysis Patients. *PLoS One*. 2016 Nov 21;11(11):e0166804.
4. Tanaka M, Yoshida K, Fukuma S, Ito K, Matsushita K, Fukagawa M, Fukuhara S, Akizawa T. Effects of Secondary Hyperparathyroidism Treatment on Improvement in Anemia: Results from the MBD-5D Study. *PLoS One*. 2016 Oct 20;11(10):e0164865.
 5. Shoji T, Niihata K, Fukuma S, Fukuhara S, Akizawa T, Inaba M. Both low and high serum ferritin levels predict mortality risk in hemodialysis patients without inflammation. *Clin Exp Nephrol*. 2017 Aug;21(4):685-693.
 6. Koiwa F, Yokoyama K, Fukagawa M, Terao A, Akizawa T. Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer hydrochloride in Japanese haemodialysis patients with hyperphosphataemia: A randomized, open-label, multicentre, 12-week phase III study. *Nephrology (Carlton)*. 2017 Apr;22(4):293-300.
 7. Ikenoue T, Fukuma S, Yamamoto Y, Yamazaki S, Akizawa T, Akiba T, Saito A, Kurokawa K, Fukuhara S. Influence of Staff Encouragement on Perceived Burden of Dietary Restriction Among Patients Living Alone. *Ther Apher Dial*. 2016 Dec;20(6):623-631.
 8. Ogata H, Fukagawa M, Hirakata H, Kaneda H, Kagimura T, Akizawa T; LANDMARK Study Group. Design and baseline characteristics of the LANDMARK study. *Clin Exp Nephrol*. 2017 Jun;21(3):531-537.
 9. Hihara K, Iyoda M, Tachibana S, Iseri K, Saito T, Yamamoto Y, Suzuki T, Wada Y, Matsumoto K, Shibata T. Anti-Phospholipase A2 Receptor (PLA2R) Antibody and Glomerular PLA2R Expression in Japanese Patients with Membranous Nephropathy. *PLoS One*. 2016 Jun 29;11(6):e0158154.
 10. Mizobuchi M, Ogata H, Yamazaki-Nakazawa A, Hosaka N, Kondo F, Koiwa F, Kinugasa E, Shibata T. Cardiac effect of vitamin D receptor modulators in uremic rats. *J Steroid Biochem Mol Biol*. 2016 Oct;163:20-7.
 11. Akizawa T, Kurita N, Mizobuchi M, Fukagawa M, Onishi Y, Yamaguchi T, Ellis AR, Fukuma S, Alan Brookhart M, Hasegawa T, Kurokawa K, Fukuhara S. PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism. *Sci Rep*. 2016 Apr 13;6:19612.
 12. Iseri K, Iyoda M, Ohtaki H, Matsumoto K, Wada Y, Suzuki T, Yamamoto Y, Saito T, Hihara K, Tachibana S, Honda K, Shibata T. Therapeutic effects and mechanism of conditioned media from human mesenchymal stem cells on anti-GBM glomerulonephritis in WKY rats. *Am J Physiol Renal Physiol*. 2016 Jun

- 1;310(11):F1182-91.
13. Yamagata K, Makino H, Iseki K, Ito S, Kimura K, Kusano E, Shibata T, Tomita K, Narita I, Nishino T, Fujigaki Y, Mitarai T, Watanabe T, Wada T, Nakamura T, Matsuo S; Study Group for Frontier of Renal Outcome Modifications in Japan (FROM-J). Effect of Behavior Modification on Outcome in Early- to Moderate-Stage Chronic Kidney Disease: A Cluster-Randomized Trial. *PLoS One*. 2016 Mar 21;11(3):e0151422.
 14. Iseri K, Iyoda M, Yamamoto Y, Kobayashi N, Oda T, Yamaguchi Y, Shibata T. Streptococcal Infection-related Nephritis (SIRN) Manifesting Membranoproliferative Glomerulonephritis Type I. *Intern Med*. 2016;55(6):647-50.
 15. Wada Y, Iyoda M, Iseri K, Arai-Nunota N, Saito T, Hamada T, Tachibana S, Ikeda M, Shibata T. Combination Therapy of Denosumab and Calcitriol for a Renal Transplant Recipient with Severe Bone Loss due to Therapy-Resistant Hyperparathyroidism. *Tohoku J Exp Med*. 2016 Mar;238(3):205-12.
 16. Yokoyama K, Kurita N, Fukuma S, Akizawa T, Fukagawa M, Onishi Y, Kurokawa K, Fukuhara S. Frequent monitoring of mineral metabolism in hemodialysis patients with secondary hyperparathyroidism: associations with achievement of treatment goals and with adjustments in therapy. *Nephrol Dial Transplant*. 2017 Mar 1;32(3):534-541.
 17. Akizawa T, Tsubakihara Y, Hirakata H, Watanabe Y, Hase H, Nishi S, Babazono T, Kumagai M, Katakura S, Uemura Y, Ohashi Y; JET-STREAM Study Group. A prospective observational study of early intervention with erythropoietin therapy and renal survival in non-dialysis chronic kidney disease patients with anemia: JET-STREAM Study. *Clin Exp Nephrol*. 2016 Dec;20(6):885-895.
 18. Fuller DS, Bieber BA, Pisoni RL, Li Y, Morgenstern H, Akizawa T, Jacobson SH, Locatelli F, Port FK, Robinson BM. International Comparisons to Assess Effects of Payment and Regulatory Changes in the United States on Anemia Practice in Patients on Hemodialysis: The Dialysis Outcomes and Practice Patterns Study. *J Am Soc Nephrol*. 2016 Jul;27(7):2205-15.
 19. 齋藤 友広, 猪口 貴子, 橘 翔平, 日原 桂, 濱田 透眞, 溝渕 正英, 柴田 孝則. 重篤な肝不全を合併した常染色体優性多発性嚢胞腎の 1 透析例 *日本透析医学会雑誌* (1340-3451) 49 巻 8 号 Page547-551 (2016. 08)
 20. 溝渕正英. Ca による FGF23 調節についての検討(原著論文). *日本透析医学会雑誌* (0914-7136) 31 巻 2 号 Page408-410 (2016. 08)

1. Ogata H, Akizawa T, Kinugasa E. What are the Newer Applications for Therapeutic Apheresis in Nephrology?: Clinical Application of Therapeutic Apheresis in Nephrology in Japan. Semin Dial. 2016 Sep;29(5):359-65.
2. 秋澤 忠男. 透析医療の現状と課題(総説). 大阪透析研究会会誌 (0912-6937)34 巻 2 号 Page99-104(2016. 09)
3. 保坂 望, 高橋 剛, 齋藤 佳範, 兼島 伸青, 本田 浩一. ケース・スタディ 発熱と右肩の疼痛を認めた維持透析患者の 1 例(症例検討会). 臨床透析 (0910-5808)32 巻 9 号 Page1198-1202(2016. 08)
4. 溝渕 正英, 井上 隆. 【最近の腎臓・透析領域の新薬とその使い方のコツ】 CKD-MBD 治療薬 ビキサロマー(解説/特集). 腎と透析 (0385-2156)81 巻 2 号 Page224-227(2016. 08)
5. 溝渕 正英, 式田 康人. 腎と透析診療指針 2016】(第 17 章)腎代替療法(腎移植を除く) 透析に伴う骨・ミネラル代謝異常(成人)(解説/特集). 腎と透析 (0385-2156)80 巻増刊 Page568-571(2016. 06)
6. 溝渕 正英, 林 純一. 【高齢化のなかでの CKD-MBD にどう対応するか?】無形成骨 (adynamic bone disease) への対策(解説/特集). 臨床透析 (0910-5808)32 巻 6 号 Page661-667(2016. 06).
7. 本田 浩一, 高橋 剛, 保坂 望. 【CKD 患者のサルコペニア・フレイル】【臨床: 合併病態】炎症(解説/特集). 腎と透析 (0385-2156)80 巻 5 号 Page699-702(2016. 05)
8. 秋澤 忠男, 加藤 徳介. 【透析膜 update-生体適合性からみた評価法と特性】透析膜の生体適合性(解説/特集). 臨床透析 (0910-5808)32 巻 5 号 Page515-520(2016. 05)
9. 本田 浩一, 高橋 剛, 兼島 伸青, 保坂 望. 【慢性腎臓病(CKD)診療を極める】CKD 患者のマネージメント 貧血(解説/特集). 内科 (0022-1961)118 巻 1 号 Page25-29(2016. 07)
10. 秋澤 忠男, 宍戸 寛治. 【保存期慢性腎臓病患者における高リン血症治療の今日的状況】(座談会/特集). Astellas Square: 明日の医療を考える (1880-0319)12 巻 3 号 Page10-14(2016. 06)
11. 式田 康人, 溝渕 正英. 【急性腎障害、慢性腎臓病-その常識は正しいか?-】透析期慢性腎臓病 その常識は正しいか? Ca 製剤の使用は予後を悪化させる(Q&A/特集). 救急・集中治療 (1346-0935)28 巻 3-4 号 Page277-284(2016. 03)
12. 本田 浩一. 【急性腎障害、慢性腎臓病-その常識は正しいか?-】透析期慢性腎臓病 その常識は正しいか? 頻回透析、長時間透析は予後を改善する(Q&A/特集). 救急・集中治療 (1346-0935)28 巻 3-4 号

Page265-269 (2016. 03).